US7759541B2 - Transgenic animals for assessing drug metabolism and toxicity - Google Patents

Transgenic animals for assessing drug metabolism and toxicity Download PDF

Info

Publication number
US7759541B2
US7759541B2 US11/757,972 US75797207A US7759541B2 US 7759541 B2 US7759541 B2 US 7759541B2 US 75797207 A US75797207 A US 75797207A US 7759541 B2 US7759541 B2 US 7759541B2
Authority
US
United States
Prior art keywords
human
mice
mouse
pxr
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US11/757,972
Other languages
English (en)
Other versions
US20080148416A1 (en
Inventor
Charles Roland Wolf
Nico Scheer
Nicole Faust
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITI Life Sciences
ITI Scotland Ltd
Original Assignee
ITI Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0427172A external-priority patent/GB0427172D0/en
Priority claimed from GB0516187A external-priority patent/GB0516187D0/en
Priority claimed from PCT/GB2005/004772 external-priority patent/WO2006064197A2/en
Priority to US11/757,972 priority Critical patent/US7759541B2/en
Application filed by ITI Life Sciences filed Critical ITI Life Sciences
Assigned to ITI LIFE SCIENCES reassignment ITI LIFE SCIENCES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WOLF, CHARLES ROLAND, FAUST, NICOLE, SCHEER, NICO
Priority to IN7390DEN2009 priority patent/IN2009DN07390A/en
Priority to JP2010510871A priority patent/JP2010528644A/ja
Priority to CA002688438A priority patent/CA2688438A1/en
Priority to AU2008259618A priority patent/AU2008259618A1/en
Priority to EP08762250A priority patent/EP2173160A1/en
Priority to US12/602,723 priority patent/US8624079B2/en
Priority to PCT/GB2008/001897 priority patent/WO2008149080A1/en
Publication of US20080148416A1 publication Critical patent/US20080148416A1/en
Priority to IL202127A priority patent/IL202127A0/en
Priority to US12/787,816 priority patent/US8212105B2/en
Publication of US7759541B2 publication Critical patent/US7759541B2/en
Application granted granted Critical
Assigned to ITI SCOTLAND LIMITED reassignment ITI SCOTLAND LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FAUST, NICOLE, SCHEER, NICO, WOLF, CHARLES ROLAND
Assigned to TACONIC BIOSCIENCES, INC. reassignment TACONIC BIOSCIENCES, INC. ASSIGNATION AND LISCENSE TERMINATION Assignors: ITI SCOTLAND LIMITED
Assigned to MIDCAP FINANCIAL TRUST reassignment MIDCAP FINANCIAL TRUST SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TACONIC BIOSCIENCES, INC.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests

Definitions

  • the present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them.
  • the transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans.
  • the transgenic non-human animals or tissues or cells derived therefrom are for use, especially but not exclusively, in assessing xenobiotic or drug metabolism, toxicity or other properties or functions of the introduced human proteins such as metabolism and/or biosynthesis of endogenous compounds.
  • One of the prior art models is also limited in that additional modifications are needed to provide cytochrome P450 reductase activity to the introduced human P450s without reactivating endogenous non-human P450s.
  • a yet further disadvantage resides in the lack of provision to reproduce human phase-2 metabolism, thus the system is unable to provide an entire metabolic profile.
  • a further disadvantage is that because the PXR or CAR genes themselves are not regulated as they are in the human by virtue of the transgene being driven by a heterologous tissue-specific promoter (albumin promoter), over-expression of the heterologous gene can occur which can have the result that a normal metabolic pathway is bypassed.
  • the PXR and CAR transgenes are derived from a cDNA rather than a genomic clone, thus the transgenic non-human animals consequently lack the sequences necessary correctly to reproduce all the transcriptional and post-transcriptional regulation of PXR or CAR expression hence their expression is restricted to the liver and may not be of a physiological level.
  • these models do not encode for splice variants of the human gene.
  • PXR/CAR models are unsuitable to combine with modifications of other genes within one animal since the humanisation of each gene is achieved by two independent genomic alterations: (i) knock-out of the endogenous gene (ii) transgenesis with the human orthologue under control of the albumin promoter at a different genomic location.
  • the present invention is the first methodology that takes into account all of the problems that prior art systems suffer from and that seeks to resolve these problems in a practical manner.
  • the inventors have recognised that in order to provide transgenic non-human animal models with humanised drug metabolism pathways that overcome the undesirable features of the animal models described in the prior art a number of criteria should ideally be satisfied:
  • non-human animal cell and non-human transgenic animals that incorporate at least some if not all of these desired qualities.
  • Such non-human animal cell and non-human transgenic animals possess desirable characteristics not available in the prior art in that they can model entire human pathways of xenobiotic metabolism rather than just individual elements of pathways and that such models are provided for all tissues and organs. This is achieved through the application of technical approaches hitherto not available in the prior art with respect to obtaining regulation of transgene expression analogous to that seen in human cells through the use of extensive regulatory DNA sequences and with respect to annulment of endogenous metabolic pathways through deletion or gene exchange. A number of relevant human proteins are expressed in a single animal.
  • a non-human animal, tissue or cells derived therefrom incorporating at least one human DNA sequence encoding at least one transcription factor under control of a transcription factor promoter and whose endogenous equivalent genes have optionally been annulled, the non-human animal, tissue or cells derived therefrom further incorporating at least one or more of the following further human DNA sequences selected from the group comprising:
  • references herein to “endogenous equivalent gene” of the non-human animal is intended to include a gene or genes whose expression product retains the same, similar or identical function as the human counterpart gene.
  • the human transcription factor gene known as PXR NR112 nuclear receptor subfamily 1, group I, member 2), Entrez GeneID: 8856
  • PXR NR112 nuclear receptor subfamily 1, group I, member 2
  • Entrez GeneID 8856
  • the proteins encoded by these genes have an equivalent function in the organisms from which they are derived.
  • the introduced transcription factor gene, the phase-1 drug-metabolising enzyme gene, the phase-2 drug-metabolising enzyme gene and/or the drug transporter protein gene will share a degree of homology with the endogenous gene with which it is equivalent.
  • the degree of homology will be greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, or even greater than 95%.
  • genes In the case of drug-metabolising enzyme genes, equivalence between genes can be assessed by a combination of substrate specificity, mode of regulation (for example, by transcription factors or exogenous drugs), sequence homology and tissue distribution. Certain genes have exact equivalents; examples of such genes are CYP2E1, CYP1A1, CYP1A2. CYP2B6 and CYP2D are examples where there is only one gene in the human, but numerous equivalent genes in the mouse. There are four CYP2C genes in the human, and numerous equivalent genes in the mouse. In such circumstances, preferably at least one, more preferably two, three, four, five or more or even all of the equivalent murine genes are annulled. CYP3A4 is an example where there is no obvious orthologue in the mouse, but Cyp3a11 could be considered at least one equivalent mouse gene because of its hepatic expression, mode of regulation and sequence homology.
  • an annulled is intended to include silencing or deletion or rendering inactive so that the non-human animal's endogenous equivalent gene is unable to express the gene product(s), at least not to any level that is significant to the drug metabolism process.
  • the expression level of an annulled gene may be less than 20%, preferably less than 10%, more preferably less than 5%, more preferably less than 2%, even more preferably 1% or less of the wild type expression level.
  • the expression of an annulled gene may preferably be decreased to the point at which it cannot be detected.
  • annulling the non-human animal's endogenous equivalent gene(s) is preferred, in some embodiments the non-human animal's endogenous equivalent gene(s) are not annulled.
  • human DNA sequences encoding proteins involved in drug metabolism may be inserted into the mouse Rosa26 locus, which does not itself result in silencing, deletion or rendering inactive of a mouse gene involved in drug metabolism.
  • cDNA sequences have been used in the prior art rather than respecting the intron/exon structure of the human gene, e.g. by incorporating at least one intron of the human gene.
  • Splice variants are important for a number of reasons. First, they may have a function. Second, they may have a dominant negative effect, for example, by binding to their usual protein partners and altering biological effects of the protein. Third, they may sequester ligand. A system that accurately reflects the in vivo situation therefore preferably mirrors the balance of splice variants that exist in any biological system.
  • cDNA also means that mRNA levels are artificially generated and may not reflect the reality of the natural physiological situation.
  • the present invention attempts to mirror the in vivo situation by providing the human gene in its entirety where this is possible. This means that the intron-exon junctions are retained as in the natural system so that splicing events can happen exactly as in the natural situation. Where, perhaps because of the length of a gene, it is not simple to transpose the entire human gene into a transgenic system, the invention seeks to use a combination of cDNA and genomic DNA in its constructs so that important intron-exon boundaries, where the majority of splicing events occur, are retained.
  • the human DNA sequence encoding a transcription factor, drug-metabolizing enzyme or drug transporter protein can be a partial human genomic gene sequence or a complete human genomic gene sequence.
  • this intron is preferably incorporated as genomic DNA in the construct, while less influential intronic sequences are not retained. This has the result that levels of functional mRNA and functional protein mirror the levels that are found in vivo in response to exposure to a particular drug or drug cocktail. This is what is ideally required for a physiologically-relevant model.
  • cDNA sequences may be used, in preference to these sequences, the invention may use a combination of cDNA and genomic sequences from the gene that is to be humanised.
  • the human DNA sequence contains some but not all of the introns and exons of the human gene.
  • a number of non-human animal models involving constructs comprising a combination of human cDNA and genomic sequences have been generated by the inventors.
  • the intron-exon structure between exons 4 and 6 is preferably maintained, since most splice variants are observed in this genomic region, since it is located within the ligand-binding domain (e.g. see FIG. 2 ). This advantageously retains the sequence where most splice variants are observed and is conveniently located within the ligand-binding domain.
  • the intron-exon structure between exons 4 and 8 of the human PXR gene is maintained (e.g. see FIG. 61 ).
  • the intron-exon structure between exons 2 and 9 of the human PXR gene is maintained (e.g. see FIG. 63 ).
  • the humanization cassette preferably used for CYP3A4 may contain the 13 kb human CYP3A4 promoter, exon 1 and intron 1 as in the normal genomic constitution and a human cDNA consisting of exons 2-13 (e.g. see FIG. 9 ).
  • the humanization cassette preferably used for CYP2C9 may contain the 12 kb human CYP2C9 promoter, a human cDNA of exons 1-4, intron 4 and a cDNA of exons 5-9 (e.g. see FIG. 10 ).
  • the humanization cassette preferably used for PPAR ⁇ may maintain the intron-exon structure between exons 3 and 8 of the human PPAR ⁇ gene, e.g. by including at least part of intron 5 and/or intron 6 (see FIG. 67 ).
  • Complete genomic DNA sequences may be used.
  • the relatively small size of the human CAR which comprises roughly 7 kb from exon 2-9, makes it simple to retain the complete genomic structure in the targeting vector.
  • the construct should preferably retain the intron-exon structure between exons 2 and 9. This advantageously retains the complete genomic structure within the targeting vector and permits coverage of all splice variants of human CAR.
  • the genomic human CAR sequence is fused to the translational start site of the mouse CAR gene.
  • the human CAR sequence then contains all genomic sequences of exons 1-9.
  • the 5′ and 3′UTRs may be human or may be retained from the mouse genome. All other parts of the coding sequences of the mouse CAR gene can be deleted.
  • genomic gene sequences may conveniently be achieved by use of a cluster of human DNA sequences, as described in more detail elsewhere herein (e.g. see FIGS. 71 , 73 and 74 ).
  • the human DNA sequence will contain all of the introns and exons of the human gene, and may optionally further comprise some or all of the regulatory sequences normally associated with the human gene (as described in more detail elsewhere herein).
  • the human DNA encoding a transcription factor is selected from the group comprising the pregnane X receptor (PXR, also known as the steroid and xenobiotic receptor SXR) and the constitutive androstane receptor (CAR) or multiples thereof or a combination thereof.
  • PXR pregnane X receptor
  • CAR constitutive androstane receptor
  • Animals and cells according to this aspect of the invention are advantageous for the reasons described in detail above. For example, recent evidence further supports the contention that the ligand binding domains of the murine and human CAR proteins are divergent relative to other nuclear hormone receptors, resulting in species-specific differences in xenobiotic responses (Huang et al., 2004, Molecular endocrinology 18(10):2402-2408). Results reported in this paper demonstrate that a single compound can induce opposite xenobiotic responses via orthologous receptors in rodents and humans.
  • Transgenic mice for human CAR have been created and are described in the examples included herein. Detailed investigations of the induction of drug metabolism pathways in CAR humanised and knock-out mice have been performed. Various different experimental approaches have confirmed that non-human transgenic animals that are humanised with respect to CAR, or which do not express any CAR (knock-out), can readily be obtained using the methods and strategies described herein.
  • the PXR protein has also been shown to be functional as the mice are responsive to compounds such as rifampicin and TCPOBOP that are known to induce gene expression via this pathway. Strain differences between wild type and the humanised mice have been demonstrated. For example, the humanised mice are shown to be more responsive to compounds such as rifampicin, that are known to be more active to hPXR. Humanised PXR animals thus demonstrated an altered sensitivity to rifampicin relative to the wild type.
  • Transgenic animals such as mice and cells according to the invention preferably demonstrate the functional properties described above and in the examples herein.
  • such cells and animals preferably do not display induction of Cyp2b10 activity in response to rifampicin.
  • such cells and animals do display an induction effect for Cyp3a11, not only with rifampicin but also for TCPOBOP.
  • human DNA(s) encoding a transcription factor may also be used in the present invention providing that they are capable of regulating a phase-1 drug-metabolising enzyme, a phase-2 drug-metabolising enzyme and/or a drug transporter protein.
  • examples include PPARs ( ⁇ , ⁇ and ⁇ ), NRF2, the Ah receptor, HNF1 and HNF4.
  • PPARs ⁇ , ⁇ and ⁇
  • NRF2 the Ah receptor
  • HNF1 HNF4
  • Targeting strategies suitable for knock-in (humanisation) and knock-out of PPAR ⁇ and the Ah receptor are described in more detail elsewhere herein (see FIGS. 67 and 68 ).
  • the human DNA encoding a transcription factor comprises both the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR).
  • PXR pregnane X receptor
  • CAR constitutive androstane receptor
  • the transgenic animal or tissue or cells derived therefrom may be considered as “double-humanised” for these transcription factor genes.
  • double-humanised models are advantageous over models that only incorporate a single gene (either PXR or CAR) because many drug metabolising enzymes or drug transporters possess elements that are responsive to the binding of both CAR and PXR.
  • the numbers of PXR-responsive elements often differ from the numbers of CAR-responsive elements and so regulation by both transcription factors is generally important. Consequently, models that take account of the effects of both factors are preferable and more closely mirror the physiological situation in vivo.
  • mice transgenic for both human PXR and human CAR have been created and are described in the examples included herein. Preliminary studies have been performed on the activity of these transcription factors in combination, determined by measuring barbiturate-induced sleeping time. Sleeping time has been known for many years to be directly proportional to the hepatic cytochrome P450 activity and this activity can be at least in part ascribed to the P450 levels in the liver determined by CAR and PXR function. Whereas wild type mice given a narcotic dose of pentobarbitone slept for 21 minutes, the double humanised mice for CAR and PXR slept for 34 minutes. These mice therefore demonstrate a significant difference to their wild type controls indicating that the double humanised mouse has a marked difference in its response to drugs relative to the wild type animals.
  • Transgenic animals such as mice and cells according to this aspect of the invention preferably demonstrate the functional properties described above.
  • cells and animals transgenic for human PXR preferably do not display induction of Cyp2b10 activity in response to rifampicin, but do display an induction effect for Cyp3a11, not only with rifampicin but also for TCPOBOP.
  • regulatory sequences of the transcription factors and the genes that they regulate should mirror the natural physiological situation as closely as possible.
  • regulatory sequences are preferably of human origin or non-human animal origin.
  • the regulatory sequences are of human origin or originate from the target non-human animal (e.g. mouse). This enables the wild-type expression pattern to be retained, as explained elsewhere herein.
  • the use of as many human transcription factors, human drug metabolising enzymes and human drug transporters as possible is important to ensure that this happens.
  • the ratio of protein levels that are generated by a particular drug are also of significant importance.
  • the action of mouse PXR stimulates expression of different proteins than the action of human PXR and at different levels.
  • the levels of a particular drug and its metabolites depends crucially on which drug metabolising enzymes and transporters are expressed and so, again, it is of utmost importance for human transcription factors to be used rather than endogenous transcription factors from another animal.
  • the regulatory sequences governing expression of the transcription factor(s) may preferably be either of human origin, or may originate from the target animal species e.g. the mouse (as described in more detail elsewhere herein).
  • genes that are inserted into the transgenic model are preferably inserted at the point in the genome where the endogenous equivalent gene or gene cluster naturally occurs. This has the advantage that the context of the gene locus is retained, which means that the fidelity of transcription from this site is as close as possible to the level of transcription that occurs in the wild type system.
  • the inventors have validated aspects of drug metabolism pathways in transgenic animals (e.g. huPXR, huCAR and huPXR/huCAR mice) using appropriate assays as described elsewhere herein.
  • the functional properties displayed by the inventors' transgenic mice in these assays reveal that the transgenic animals, tissues and cells of the invention have significant utility in analysis of drug metabolism and toxicity.
  • the inventors validated aspects of drug metabolism pathways in transgenic animals using inducers of the components of those pathways that are known to act more potently in humans or in mice, as summarised below:
  • Rifampicin human CITCO human Phenobarbital (PB) mouse/human Dexamethasone (Dex) mouse 5-Pregnen-3 ⁇ -ol-20-one-16 ⁇ - mouse carbonitrile (PCN)
  • Clotrimazole mouse TCPOBOP mouse Species-specific inducers of drug metabolism, such as those listed above, may act primarily via CAR or PXR, or via both PXR and CAR (e.g. see FIG. 55 ).
  • the species-specific induction of CAR and PXR can be discriminated using assays that allow a distinction to be made between induction via PXR and incuction via CAR, such as by measuring Cyp3a11 or Cyp2b10 levels or activity (e.g. see FIG. 48 ).
  • assays that allow a distinction to be made between induction via PXR and incuction via CAR, such as by measuring Cyp3a11 or Cyp2b10 levels or activity (e.g. see FIG. 48 ).
  • An overview of the effects of the inducers listed above on induction of Cyp3a11 and Cyp2b10 in mice and humans is provided in FIGS. 55 and 83 .
  • the invention provides a transgenic mouse, tissue or cells derived therefrom incorporating a human DNA sequence encoding PXR under the control of an endogenous promoter, and optionally having its equivalent endogenous murine PXR genes annulled, which mouse, tissue or cells:
  • the invention also provides a transgenic mouse, tissue or cells derived therefrom incorporating a human DNA sequence encoding CAR under the control of an endogenous promoter, and optionally having its equivalent endogenous murine CAR genes annulled, which mouse, tissue or cells:
  • Cytochrome P450 expression and activity levels can be determined by appropriate assays, as described elsewhere herein (see FIG. 48 ).
  • cytochrome P450 e.g. Cyp3a11 or Cyp2b10 expression levels can be determined by western blotting.
  • Cytochrome P450 activity can be determined by a 7-benzyloxyquinoline (BQ) activity assay (for Cyp3a) or a pentoxyresorufin-O-deethylation (PROD) activity assay (for Cyp2b).
  • BQ 7-benzyloxyquinoline
  • PROD pentoxyresorufin-O-deethylation
  • the invention also provides a transgenic mouse, tissue or cells derived therefrom that possesses a combination of the functional properties mentioned herein.
  • the invention provides a transgenic mouse, tissue or cells derived therefrom incorporating human DNA sequences encoding PXR and CAR under the control of endogenous promoters, and optionally having its equivalent endogenous PXR and CAR genes annulled, which mouse, tissue or cell:
  • the invention also provides a transgenic mouse, tissue or cells derived therefrom incorporating a human DNA sequence encoding PXR under the control of an endogenous promoter, and optionally having its equivalent endogenous PXR gene annulled, which displays increased dexamethasone-mediated hepatotoxicity relative to the corresponding wild-type mouse.
  • Dexamethasone-mediated hepatotoxicity can be determined by measuring ALT levels using an appropriate assay and an appropriate dose of dexamethasone (e.g. at least 20 mg/kg, at least 30 mg/kg, at least 40 mg/kg, at least 50 mg/kg, or at least 60 mg/kg. Suitable assays are described elsewhere herein.
  • transgenic mice containing altered transcription factor genes are described in more detail elsewhere herein.
  • PXR humanisation is achieved by two independent genomic alterations: (i) knock-out of the endogenous PXR gene, and (ii) transgenesis with the human PXR gene at a different genomic location.
  • the human DNA encoding a phase-1 drug-metabolising enzyme is selected from the group comprising the cytochromes P450, including but not limited to CYP1A1, CYP1A2, CYP3A4, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP2B6.
  • cytochromes P450 including but not limited to CYP1A1, CYP1A2, CYP3A4, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP2B6.
  • other DNAs encoding a phase-1 drug-metabolising enzyme may also be included in the present invention, providing that they are capable of modifying a xenobiotic by adding or exposing a polar group on the xenobiotic molecule.
  • human P450 isoforms for introduction into P450-humanised non-human animals is predominantly driven by the known relative importance of various P450 isoforms in metabolism in the relevant tissue.
  • CYP3A4 the single most significant P450 isoform recognised in the human liver is CYP3A4
  • CYP3A4 is therefore probably the first human P450 isoform of choice for P450 humanisation of liver.
  • the choice of human P450s for the multi-P450-humanised mouse of the present invention is dictated by the need of the user. In this respect it is expected that any one or more of the following human isoforms will be preferred: 3A4, 2D6, 2B6, 2C9, 2C19, 1A1, 1A2, 2C8.
  • the isoform(s) incorporated into the animal cell is/are dependent on the user's requirement. In this way, the humanised transgenic animal may be “designed” to investigate the role of specific isoforms in the metabolic process.
  • single genes, gene clusters or combinations of single genes or gene clusters may be replaced.
  • Whole gene clusters should preferably be replaced where possible, rather than simply replacing individual genes. This generates a situation in which the ratios of the expression levels of genes in any gene cluster are the same as the ratios in which these genes are expressed in vivo. This is a phenomenon that has not received attention in the prior art.
  • the CYP3A, CYP2C and CYP2D clusters are preferred clusters of phase-1 drug-metabolising enzymes for replacement according to the present invention. Either one, both or even all of these gene clusters may be replaced according to the present invention.
  • partial, or preferably complete cascades of genes that are implicated in a particular pathway may preferably be replaced.
  • This ensures that the partial redundancy of gene function is retained and so, again, the real physiological situation is mirrored.
  • An example can be provided by the CYP3A P450 cluster.
  • the CYP3A5 protein will, for example, metabolise CYP3A4 substrates. Therefore, if one is attempting to generate a model of drug metabolism, incorporating the CYP3A5 gene in any state other than as part of its entire gene cluster is distancing the generated model from reality.
  • the clusters of phase 1 drug metabolising enzymes that are used for humanisation are the CYP3A cluster and the CYP2C cluster.
  • humanisation for phase 1 drug metabolising enzymes is preferably performed against a deleted background in which only some (for example 1, 2, 3, 4 or 5), and preferably none of the target animal phase 1 drug metabolising enzymes are expressed at significant levels.
  • mice containing altered phase-1 drug-metabolising enzyme genes are described in more detail elsewhere herein.
  • the human DNA encoding a phase-2 drug-metabolising enzyme is selected from the group comprising the glucuronyl transferases, for instance, the UGT1A gene or gene cluster, the glutathione transferases, for instance GST (glutathione S-transferases), the sulphonyl transferases and the acetyl transferases.
  • the glucuronyl transferases for instance, the UGT1A gene or gene cluster
  • the glutathione transferases for instance GST (glutathione S-transferases)
  • the sulphonyl transferases for instance GST (glutathione S-transferases)
  • sulphonyl transferases for instance GST (glutathione S-transferases)
  • acetyl transferases for instance, the acetyl transferases.
  • other DNAs encoding a phase-2 drug-metabolising enzyme may also be included in the present invention providing that they are capable of conjugating a product of phase
  • a cluster of phase 2 drug metabolising enzymes that is used for humanisation is the UGT1A gene cluster.
  • mice containing altered phase-2 drug-metabolising enzyme genes are described in more detail elsewhere herein.
  • the human DNA encoding a drug transporter protein is selected from the group comprising the ATP-binding cassette proteins which include but are not limited to the multi-drug resistance proteins, for instance MDR-1 and multi-drug resistance-associated proteins (MRPs), for example, MRP1 and/or MRP2, or from the organic anion transporting polypeptides (OATPs).
  • MRPs multi-drug resistance proteins
  • OATPs organic anion transporting polypeptides
  • the multidrug resistance protein is MDR1.
  • the multi-drug resistance-associated protein is MRP2.
  • mice containing altered drug transporter protein genes are described in more detail elsewhere herein.
  • the present invention resides in part in the humanisation of transgenic non-human animal cell, tissue or animals especially for transcriptional factor(s), wherein the transcriptional factor transgenes are driven by transcriptional factor promoters, that is to say they are “knocked-in” rather than utilising heterologous albumin/tissue specific promoters.
  • the animals of the present invention are able to express the human proteins at not only the appropriate physiological levels but in all tissues, rather than just the liver as is known from the prior art.
  • any human DNA sequences include coding sequences for proteins selected from the group of classes of: human phase-1 metabolism enzymes; human phase-2 metabolism enzymes; human drug transporters; human transcription factors, may ideally be operatively linked to human regulatory DNA sequences.
  • human regulatory sequences is not essential, and other endogenous regulatory sequences can be used, e.g. mouse sequences.
  • these human DNA sequences of the above-described transcription factors and other proteins are whole genes or are DNA constructs comprising regulatory sequences that may either be derived from humans or animals.
  • the regulatory sequences may be derived from the target animal, for example, the mouse.
  • regulatory sequences is meant to include any promoter or enhancer sequences, 5′ or 3′ UTRs, poly-A termination sequences or other DNA sequences, that are necessary for transcription of the gene of interest or which modulate expression of the gene of interest.
  • Transcripts used for insertion of human sequences are preferably terminated by a poly A motif.
  • Heterologous promoters have generally been used in the prior art, and those used (such as the albumin promoter) are generally strong promoters, are ligand independent in their action and are constitutively switched on. In normal development, albumin is only expressed neo-natally. This divorces the expression of the protein encoded by the gene from the natural situation in reality, in that the regulatory signals that direct transcription of the gene and the subsequent translation of the mRNA product are not retained in the transgenic system.
  • researchers in the prior art turned to the use of such promoters for a variety of reasons. Partly, it was felt necessary to do so because the transcription signals provided by the endogenous promoters were not deemed to be strong enough. Furthermore, it was thought necessary to use promoters that had been shown to be effective in the mouse.
  • the invention preferably incorporates the endogenous promoter with the human gene so that the fidelity of wild type human expression is retained, developmentally, temporally and in a tissue-specific manner.
  • endogenous promoter is meant a promoter that naturally directs expression of the gene of interest.
  • An endogenous promoter may thus be a human promoter, or may alternatively be the promoter that is endogenous to that introduced gene in the transgenic animal subject.
  • the expression of the human gene may be directed by the endogenous mouse promoter for that gene.
  • it is not essential to insert a human regulatory sequence, e.g. a human promoter.
  • the endogenous promoter in its entirety, is perfectly capable of directing expression of the relevant protein in a physiologically relevant manner.
  • An example is provided by the CYP3A4 gene, which possesses strong enhancer elements up to 13 kb upstream of the transcription initiation point. Whilst incorporation of all this sequence allows the appropriate mechanism of transcription to occur, omission of these upstream sequences leads to a system in which incomplete or insufficient regulatory sequences are present to allow the fidelity of gene expression to be retained.
  • non-human animal's endogenous regulatory sequences may be preferred.
  • Such embodiments allow expression of human DNA sequences under the control of the non-human animal's endogenous regulatory sequences, such that the components of the non-human animal's gene expression pathway (e.g. regulatory sequences, transcription factors) can interact.
  • Such embodiments may more closely mirror the in vivo situation in humans in some cases, e.g. where the relevant human regulatory sequence is not capable of interacting with the non-human animal's transcription factors, or said interaction does not provide a relevant level of expression of the human DNA sequence.
  • a human DNA sequence is expressed under the control of mouse promoter.
  • the invention also provides a transgenic non-human animal (e.g. mouse), tissue or cells derived therefrom incorporating a human DNA sequence encoding a protein involved in drug metabolism, wherein said human DNA sequence is operatively linked to an endogenous regulatory sequence of the non-human animal, and the endogenous equivalent gene in the non-human animal is optionally annulled.
  • a transgenic non-human animal e.g. mouse
  • tissue or cells derived therefrom incorporating a human DNA sequence encoding a protein involved in drug metabolism, wherein said human DNA sequence is operatively linked to an endogenous regulatory sequence of the non-human animal, and the endogenous equivalent gene in the non-human animal is optionally annulled.
  • the inventors are of the view that the liver is not the only important tissue for drug metabolism. Accordingly, what the prior art workers perceived as an advantage, i.e. that exclusive liver-specific expression enabled an accurate assessment of the real physiological situation, the inventors see as a distinct disadvantage because other potentially important tissues are ignored.
  • the invention allows a global, holistic snapshot to be obtained of the drug metabolism process.
  • the endogenous promoter also carries other advantages with it.
  • the fidelity of developmental expression is retained.
  • prior art systems have used liver-specific promoters that sponsor liver expression exclusively, the use of the natural endogenous promoter ensures that the protein is expressed in the tissues in which it naturally occurs, and not only in the adult animal, but also at each developmental stage. This also carries with it the advantage that the transgenic animals are more likely to be viable and thus useful as drug screens and in the development of downstream crosses. It also allows the animals to be used to screen for teratogenic effects of a test compound, as placental expression of transcription factors and drug metabolising enzymes is retained.
  • the inventors have also noted the existence of a potential “repression” effect whereby a particular drug compound reduces the level of a particular drug transporter or metabolising enzyme and so alters the rate or pathway of disposition.
  • a potential “repression” effect whereby a particular drug compound reduces the level of a particular drug transporter or metabolising enzyme and so alters the rate or pathway of disposition.
  • an alternative pathway of disposition may be exaggerated. This would give a misleading impression of the enzyme levels that are induced by a particular drug in an organism. It would also give a misleading impression of the rate and type of metabolism that would operate in the human on exposure to that particular drug.
  • the inventors have also noted that the duration of induced expression by a particular drug is of great importance. For example, some drugs that are candidates for use in humans may not be metabolised efficiently in the mouse. This means that such a drug remains present at a systemically high concentration for a significant period. This means that transcription factors such as PXR will remain activated for this period, being constantly activated for this period. Associated levels of drug metabolising enzymes, drug transporters and other such enzymes will as a result also be highly expressed during the entire period that the drug remains in the animal. This clearly is misleading and in contrast to the equivalent situation in the human where the metabolism of the drug may be significantly more efficient.
  • Using the human promoter rather than the mouse promoter may be preferable to drive the expression of transcription factors, phase 1 drug metabolising enzymes, phase 2 drug metabolising enzymes, and/or drug transporters, as it allows the idiosyncrasies of the human expression system to be retained.
  • these have a different number of PXR and CAR response elements to the number that is present in the human CYP3A4 gene.
  • the equivalent mouse promoter to be used, then the response to transcriptional activation of PXR by exposure of the animal to drug would be correspondingly different to the response that is evident in a human system.
  • CYP3A4 In contrast, using the natural human promoter means that, following this example, the appropriate amount of CYP3A4 would be produced in response to drug activation, and furthermore, would be produced in the correct tissue.
  • the natural physiological response to a particular drug will then be mimicked, in terms of the amount of CYP3A4 that is produced, not only in the liver, but also, say, in the gastro-intestinal tract. If the drug is in fact a substrate for CYP3A4, then it will be metabolised at a rate and in a manner that mirrors the situation in the human.
  • a prior art method that uses an albumin promoter to direct expression of inappropriately large amounts of CYP3A4 will distort the role of this protein and give misleading results. For instance, the drug might in fact only be a weak substrate for CYP3A4, but will nevertheless be metabolised aggressively if high amounts of the protein are present.
  • regulatory sequences are preferably of human origin or non-human animal origin.
  • the regulatory sequences are of human origin or originate from the target non-human animal (e.g. mouse). This enables the wild-type expression pattern to be retained (developmentally, temporally and spatially).
  • the target gene and the human incorporated gene may share a leader sequence. This may be achieved by retaining at least one intron from the target non-human animal gene in the construct, which usually results in a better expression. This strategy also ensures that the gene product will be guided to the right intracellular location.
  • the human leader sequence might be able to fulfil that function as well, but it is often safer to use the mouse leader instead. For instance, in the case of MRP2, the “leader sequence” of the mouse protein, which is encoded by exon 1, may be retained. The human cDNA without sequences from exon 1 is then introduced into exon 2 of the mouse genomic sequence.
  • mouse intron 1 The original splice sites for mouse intron 1 will be retained, so that this construct encodes a fusion protein of amino acids from mouse exon 1 and human exons 2-32. This construct ensures a high level of expression and also that the MRP2 is guided to its correct location, the plasma membrane.
  • the incorporated human gene may be brought under control of the promoter of the appropriate target animal gene.
  • the cDNA of human MDR1 may be fused to the translational start site of the corresponding mouse genes (Mdr1a or Mdr1b).
  • Mdr1a or Mdr1b the corresponding mouse genes
  • PXR a hybrid of human PXR cDNA and genomic sequences may be fused to the translational start site of the mouse PXR gene, whereby the mouse Start-ATG is retained.
  • the human sequence may be fused to the translational start site of the mouse CAR gene.
  • the invention provides a transgenic non-human animal, tissue or cells derived therefrom incorporating a human DNA sequence encoding a protein involved in drug metabolism under the control of an endogenous regulatory sequence, wherein the human DNA sequence comprises at least one intron, such that at least one splice variant is produced when the human DNA sequence is transcribed in the transgenic non-human animal, tissue or cells derived therefrom.
  • the endogenous equivalent gene encoding the protein in the non-human animal is optionally annulled.
  • the protein involved in drug metabolism is a transcription factor, a phase-1 drug-metabolising enzyme, a phase-2 drug-metabolising enzyme and/or a drug transporter protein as described elsewhere herein.
  • the protein involved in drug metabolism is a phase-1 or phase-2 drug-metabolizing enzyme, as described elsewhere herein.
  • the protein involved in drug metabolism is a drug transporter protein as described elsewhere herein.
  • the invention provides a transgenic non-human animal, tissue or cells derived therefrom incorporating a human DNA sequence encoding a cluster of proteins involved in drug metabolism under the control of endogenous regulatory sequences.
  • a corresponding cluster of endogenous equivalent genes is optionally annulled.
  • the intron-exon structure of the human DNA sequence is maintained (i.e. genomic sequences rather than cDNA sequences are used, as described elsewhere herein).
  • the invention provides non-human animals, tissue or cells derived therefrom into which a human DNA sequence encoding a protein involved in drug metabolism has been inserted, and in which an endogenous gene encoding a protein involved in drug metabolism is optionally annulled.
  • non-human animals, tissues or cells derived therefrom in which an endogenous gene for a protein involved in drug metabolism has been annulled, and which do not further comprise a human DNA sequence encoding a protein involved in drug metabolism are also useful in the invention.
  • knock-out non-human animals, tissues or cells are particularly useful in parallel with the “knock-in” (humanised) non-human animals, tissues or cells of the invention, because comparison of experimental data generated using knock-in and knock-out mice can reveal further useful information regarding pathways of drug metabolism.
  • the invention provides a method for investigating xenobiotic metabolism or toxicity, comprising the use of:
  • Preferred non-human animals of type (i) include those specified elsewhere herein (e.g. those having the genotype huPXR, huCAR, huPPAR ⁇ , huAhR, huCYP3A4, huCYP3A cluster, huCYP2C9, huCYP2C cluster, huCYP2D6, huCYP1A1/1A2, huUGT, huMDR1/mdr1a ⁇ / ⁇ , huMDR1/mdr1b ⁇ / ⁇ , huMDR1/mdr1a ⁇ / ⁇ /mdr1b ⁇ / ⁇ , or huMRP2).
  • Preferred non-human animals of type (ii) include those specified elsewhere herein (e.g. those having the genotype koPXR, koCAR, koPPAR ⁇ , koAhR, koCyp3a11, koCyp3a cluster, koCyp2c cluster, koCyp1a1/Cyp1a2, koCyp2d cluster, or koUGT).
  • such methods may involve e.g., comparing drug metabolism in (i) a non-human animal with the genotype huPXR, and (ii) a non-human animal with the genotype koPXR (and optionally (iii) a wild-type non-human animal).
  • such methods comprise the use of:
  • Such methods may involve e.g., comparing drug metabolism in (i) non-human animals with the genotypes huPXR, huCAR, huCYP2C cluster, huUGT, and (ii) non-human animals with the genotypes koPXR, koCAR, koCyp2c cluster, koUGT (and optionally (iii) a wild-type non-human animal).
  • the invention provides a method for investigating xenobiotic metabolism or toxicity, comprising the use of:
  • drug metabolism can be compared between (i) a first non-human animal with the genotype huPXR, wherein the human DNA sequence encoding PXR is under the control of an endogenous human regulatory sequence, and (ii) a second non-human animal with the genotype huPXR, wherein the human DNA sequence encoding PXR is under the control of an endogenous non-human animal regulatory sequence (and optionally (iii) knock-out and/or (iv) wild-type non-human animals).
  • Such methods enable subtle differences in gene regulation and expression levels between humans and model organisms (e.g. mice) to be elucidated.
  • non-human animals, tissues or cells derived therefrom as disclosed herein.
  • the type and number of non-human animals, tissues or cells required for comparison will depend on the type of analysis required (e.g. depending on the drug metabolism pathway of interest and/or the drug of interest).
  • the invention provides transgenic non-human animals, tissues or cells derived therefrom of various genotypes (see elsewhere herein).
  • the invention provides a tool kit from which the skilled person can select the tools required for the desired analysis.
  • the invention provides a method for investigating xenobiotic metabolism or toxicity, comprising the use of at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten types of non-human animal, tissue or cells derived therefrom, wherein each type of non-human animal, tissue or cells comprises a different genetic modification (e.g. knock-in, knock-out, altered regulatory sequence) affecting the amino acid sequence or expression of a protein involved in drug metabolism.
  • a different genetic modification e.g. knock-in, knock-out, altered regulatory sequence
  • the ‘holistic’ methods disclosed herein in which multiple different types of transgenic non-human animal, tissue or cells are compared, enable a more rigorous analysis of drug metabolism and toxicity than the prior art methods that involve use of fewer types of transgenic non-human animal, tissue or cell.
  • the methods of the invention wherein different transgenic non-human animals are compared may involve administering the same drug at the same dose to the different types of non-human animal (e.g. “knock-in”, “knock-out” and wild-type, human or non-human regulatory sequences) and comparing the metabolism or toxicity of that drug between the different animals.
  • non-human animal e.g. “knock-in”, “knock-out” and wild-type, human or non-human regulatory sequences
  • the transgenic non-human animal and tissues or cells derived therefrom is preferably a mouse but may be another mammalian species, for example another rodent, for instance a rat, hamster or a guinea pig, or another species such as a monkey, pig, rabbit, or a canine or feline, or an ungulate species such as ovine, caprine, equine, bovine, or a non-mammalian animal species. More preferably, the transgenic non-human animal or mammal and tissues or cells are derived from a rodent, more preferably, a mouse.
  • transgenic animals pose questions of an ethical nature, the benefit to man from studies of the types described herein is considered vastly to outweigh any suffering that might be imposed in the creation and testing of transgenic animals.
  • drug therapies require animal testing before clinical trials can commence in humans and under current regulations and with currently available model systems, animal testing cannot be dispensed with. Any new drug must be tested on at least two different species of live mammal, one of which must be a large non-rodent. Experts consider that new classes of drugs now in development that act in very specific ways in the body may lead to more animals being used in future years, and to the use of more primates.
  • transgenic models such as those described herein is not in any limited to mice, or to rodents generally, but encompasses other mammals including primates.
  • the specific way in which these novel drugs will work means that primates may be the only animals suitable for experimentation because their brain architecture is very similar to our own.
  • the invention aims to reduce the extent of attrition in drug discovery. Whenever a drug fails at a late stage in testing, all of the animal experiments will in a sense have been wasted. Stopping drugs failing therefore saves test animals' lives. Therefore, although the present invention relates to transgenic animals, the use of such animals should reduce the number of animals that must be used in drug testing programmes.
  • An advantage of the present invention is that it avoids problems of species divergence between the human and other mammals that have conventionally been used as test models.
  • One example is provided by the family of peroxisome proliferator activated receptors (PPARs), to which various drugs were in the past developed as hypolipidaemia agents. The development of these drugs was stopped, as they were identified in mouse models to be epigenetic carcinogens. It eventually turned out that that the difference in toxicity between species could be attributed to differences in levels of PPAR ⁇ in the liver. The phenomenon apparent in the mouse does not occur in humans, because of lower levels of PPAR ⁇ protein that are present in the liver. There are very clear advantages to models that exhibit bona fide levels of protein expression that reflect those present in the human body.
  • the human DNA sequences are each independently linked to human or non-human animal regulatory DNA sequences (e.g. the endogenous human or non-human promoter).
  • human or non-human animal regulatory DNA sequences e.g. the endogenous human or non-human promoter.
  • This linkage is distinct from the prior art and provides the advantage of improvement over prior art models as this further advances the mirroring of an in vivo human situation.
  • humanised transgenic animals, cells and tissues, of the present invention are combined the benefits of normal experimental animal models with those of human cell or tissue culture in a single system.
  • This system or humanised transgenic animal will provide the pharmaceutical industry with an improved alternative for use in all pre-clinical metabolism, toxicity and drug disposition studies.
  • Hepatocytes and neuronal cells are preferred cell types according to the present invention.
  • the cells may be animal cells, including mammalian cells, such as non-human cells or rodent cells, more specifically, mouse cells.
  • Cells according to this aspect of the invention may be created from transgenic animals according to the invention using standard techniques, as will be clear to the skilled reader, imbued with knowledge of the present invention. Suitable methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986); Sambrook Molecular Cloning; A Laboratory Manual, Third Edition (2000); Ausubel et al., 1991 [supra]; Spector, Goldman & Leinwald, 1998).
  • such cells may be non-human animal cells, such as mouse cells, generated according to any one of the above-described aspects of the invention.
  • One preferred method of generating such cells is to cross a humanised mouse, as described above, with SV40 immortalised mouse (for example, the immorta-mouse (Taconix). Cells may subsequently be isolated from such animals according to well known techniques in the art.
  • SV40 immortalised mouse for example, the immorta-mouse (Taconix).
  • Cells may subsequently be isolated from such animals according to well known techniques in the art.
  • cells from transgenic animals generated according to the present invention may be of a diverse selection of different cell types, including cells of significant importance to pharmacokinetics analyses, such as hepatocytes and neuronal cells.
  • Stem cells isolated from transgenic animals according to the invention are also useful aspects of the present invention.
  • Such cells may be pluripotent, or partially differentiated.
  • Stem cells may be adult stem cells or embryonic stem cells. More generally, stem cells employed may be from a post-embryonic developmental stage e.g. foetal, neonatal, juvenile, or adult.
  • Stem cells isolated in this manner may be used to generate specific types of cells such as hepatocytes and neuronal cells. Such cells also form an aspect of the present invention.
  • non-human animal, tissue or cells derived therefrom incorporating:
  • the inventors are of the view that in the case of models of drug metabolism, it is important to generate animals that are not just transgenic for particular drug metabolising enzymes, but also to incorporate in these models, proteins that are transporters of drugs i.e. drug transporter proteins.
  • proteins that are transporters of drugs i.e. drug transporter proteins.
  • drugs transporter proteins many compounds that activate PXR, the nuclear transcription factor, are also substrates for MDR1 and are thus transported out of cells by this protein. Therefore, in order to create a faithful model of the in vivo situation, animals must preferably be transgenic for drug transporter proteins, otherwise a misleading impression will be obtained of the intracellular effects of any particular concentration of drug.
  • MDR1 is preferred.
  • genes encoding drug transporter proteins such as MDR1 is also activated by the PXR-based signalling system. Accordingly, because the expression of the phase I, phase II and drug transporter genes is linked by PXR, in addition to the fact that the products of these genes have varied effects on the levels and metabolism of drugs and their metabolites, the integrity of co-ordinated regulation that is maintained according to the present invention is extremely advantageous, particularly when compared to prior art systems.
  • MDR is expressed at a significant degree in the gastro-intestinal (GI) tract and in the environment of the blood-brain barrier. Since both the GI tract and the blood brain barrier are significant sources of drug transport into the blood stream, the presence of physiologically-relevant MDR expression levels imparts an important aspect of the drug metabolism process to the drug model and in demonstrating pharmacological activity. The presence of MDR in the GI tract, for example, can render orally-delivered drug not bioavailable. MDR is very important for drug transport both in an out of the brain. MDR also transports drugs from somatic cells in the liver into the bile.
  • GI gastro-intestinal
  • non-human animal, tissue or cells derived therefrom incorporating:
  • non-human animal, tissue or cells derived therefrom incorporating:
  • non-human animal, tissue or cells derived therefrom incorporating:
  • these aspects include any one or more of the features hereinbefore described.
  • one or more of the human DNA sequences is a partial or complete genomic sequence as described elsewhere herein.
  • a non-human animal, tissue or cells derived therefrom incorporating human DNA sequences encoding a PXR and a CAR transcription factor and at least one human DNA sequence encoding a phase-1 drug-metabolising enzyme and at least one human DNA sequence encoding a phase-2 drug-metabolising enzyme and at least one human DNA sequence encoding a drug transporter protein, wherein the endogenous equivalent genes in the non-human animal, tissue or cells have optionally been annulled.
  • a non-human animal, tissue or cells derived therefrom incorporating:
  • transgenic non-human animals, tissues and cells of the invention have a genotype as specified in the following list.
  • the prefix “hu” refers to humanisation of the relevant endogenous non-human animal gene
  • the prefix “ko” refers to a knock-out of the relevant endogenous non-human animal gene.
  • references to genes and genotypes herein that are in capitals refer to a human gene or gene cluster (and possibly also to a gene or gene cluster in a non-human animal), whereas references to genes and genotypes not in capitals (e.g. Cyp3a11) refer to a gene or gene cluster in a non-human animal (e.g. mouse).
  • transgenic non-human animals, tissues and cells of the invention incorporate a combination of two or more of the genotypes described herein, some examples of which are specified in the following list, wherein the symbol “/” indicates a combination of relevant genotypes.
  • Transgenic non-human animals, tissues and cells having a combination of two or more genetic manipulations as described herein are particularly preferred, because the drug metabolism pathways in those non-human animals, tissues and cells more closely resemble the in vivo situation in humans.
  • Such non-human animals, tissues and cells may incorporate 2 or more, 3 or more, 4, or more 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more of the genetic manipulations as described herein.
  • the invention provides a method of introducing into a non-human animal cell at least one human DNA sequence encoding a protein involved in drug metabolism using a targeting strategy or targeting vector(s) substantially as described herein or substantially as depicted in the Figures herein.
  • the invention provides a transgenic mouse, tissue or cells derived therefrom comprising one or more of the following features:
  • the DNA sequence encoding human PXR preferably comprises at least part of intron 4 and/or intron 5 of the human PXR gene (e.g. FIGS. 2 and 64).
  • the DNA sequence encoding human PXR may further comprise at least part of intron 6 and/or intron 7 of the human PXR gene (e.g. FIG. 61).
  • the DNA sequence encoding human PXR may further comprise at least part of intron 2, intron 3 and/or intron 8 of the human PXR gene (e.g. FIG. 63).
  • the targeting vector(s) preferably include sequence elements that enable PXR knock-out (e.g. Phi-C31-mediated knock-out) to produce koPXR.
  • huCAR Knock-in of a DNA sequence encoding human CAR into the and mouse CAR locus enabling expression of human CAR under the koCAR control of the mouse CAR promoter.
  • the DNA sequence encoding human CAR preferably comprises at least part of intron 2, intron 3, intron 4, intron 5, intron 6, intron 7 and/or intron 8 of the human CAR gene (e.g. FIG. 3).
  • the targeting vector(s) preferably include sequence elements that enable CAR knock-out (e.g. Phi-C31-mediated knock-out) to produce koCAR.
  • CAR knock-out e.g. Phi-C31-mediated knock-out
  • huPPAR ⁇ Knock-in of a DNA sequence encoding human PPAR ⁇ into the and mouse PPAR ⁇ locus, enabling expression of human PPAR ⁇ koPPAR ⁇ under the control of the mouse PPAR ⁇ promoter.
  • the DNA sequence encoding human PPAR ⁇ preferably comprises at least part of intron 5 and/or intron 6 of the human PPAR ⁇ gene (e.g. FIG. 67).
  • the targeting vector(s) preferably include sequence elements that enable PPAR ⁇ knock-out (e.g. Cre-mediated knock-out) to produce koPPAR ⁇ .
  • PPAR ⁇ knock-out e.g. Cre-mediated knock-out
  • huAhR Knock-in of a DNA sequence encoding human AhR into the and mouse AhR locus enabling expression of human AhR under the koAhR control of the mouse AhR promoter.
  • the DNA sequence encoding human AhR preferably comprises exons 3-11 of the human AhR gene (e.g. FIG. 68).
  • the targeting vector(s) preferably include sequence elements that enable AhR knock-out (e.g. Cre-mediated knock-out) to produce koAhR.
  • the DNA sequence encoding human CYP3A4 preferably comprises at least part of intron 1 of the human CYP3A4 gene (e.g. FIG. 69).
  • koCyp3a11 Knock-in of ZsGreen reporter gene into the mouse Cyp3a11 locus, enabling expression of ZsGreen under the control of the mouse Cyp3a11 promoter e.g. FIG. 70).
  • huCYP3A Insertion of a DNA sequence encoding the human CYP3A cluster cluster into the mouse Cyp3a cluster, enabling expression of the human and CYP3A cluster under the control of human CYP3A promoters.
  • the targeting vector(s) preferably include sequence elements that cluster enable Cre-mediated deletion of the mouse Cyp3a cluster, to produce koCyp3a (e.g. FIG. 71).
  • the targeting vector(s) preferably include sequence elements that enable Cre-mediated insertion of the human CYP3A cluster subsequent to Cre-mediated deletion of the mouse Cyp3a cluster, to produce huCYP3A.
  • the targeting vector(s) preferably include sequence elements that enable deletion of selection cassettes subsequent to insertion of the human CYP3A cluster into the mouse Cyp3a cluster.
  • huCYP3A4 Knock-in of a DNA sequence encoding human CYP3A4 into the and koCyp3a mouse Cyp3a cluster, enabling expression of human CYP3A4 cluster under the control of a human CYP3A4 promoter. Mice in which the Cyp3a cluster is deleted may also be generated.
  • huCYP2C9 Knock-in of a DNA sequence encoding human CYP2C9 into the mouse Rosa26 locus, enabling expression of human CYP2C9 under the control of a human CYP2C9 promoter.
  • the DNA sequence encoding human CYP2C9 preferably comprises at least part of intron 4 of the human CYP2C9 gene (e.g. FIG. 72).
  • koCyp2c The targeting vector(s) preferably include sequence elements that cluster enable Cre-mediated deletion of the mouse Cyp2c cluster, to produce koCyp2c (e.g. FIG. 73).
  • the targeting vector(s) preferably include sequence elements that enable Cre-mediated insertion of the human CYP2C cluster subsequent to Cre-mediated deletion of the mouse Cyp2c cluster, to produce huCYP2C.
  • the targeting vector(s) preferably include sequence elements that enable deletion of selection cassettes subsequent to insertion of the human CYP2C cluster into the mouse Cyp2c cluster.
  • huCYP2C9 Knock-in of a DNA sequence encoding human CYP2C9 into the and koCyp2c mouse Cyp2c cluster, enabling expression of human CYP2C9 cluster) under the control of a human CYP2C9 promoter. Mice in which the Cyp2c cluster is deleted may also be generated.
  • huCYP2D6 Knock-in of a DNA sequence encoding human CYP2D6 into the and koCyp2d mouse Cyp2d cluster enabling expression of human CYP2D6 cluster under the control of a human CYP2D6 promoter. Mice in which the Cyp2d cluster is deleted may also be generated.
  • huCYP3A4 Knock-in of a DNA sequence encoding human CYP3A4 into the and mouse Cyp3a cluster enabling expression of human CYP3A4 koCyp3a11 under the control of the mouse Cyp3a11 promoter. Mice in which the Cyp3a cluster is deleted may also be generated.
  • CYP1A2 Mice in which the Cyp1a cluster is deleted may also be generated.
  • the targeting vector(s) preferably include sequence elements that cluster enable Cre-mediated deletion of the mouse Ugt1 cluster, to produce koUGT (e.g. FIG. 74).
  • the targeting vector(s) preferably include sequence elements that enable Cre-mediated insertion of the human UGT1 cluster subsequent to Cre-mediated deletion of the mouse Ugt1 cluster, to produce huUGT.
  • the targeting vector(s) preferably include sequence elements that enable deletion of selection cassettes subsequent to insertion of the human UGT1 cluster into the mouse Ugt1 cluster.
  • huMDR1/mdr1a /— Knock-in of a DNA sequence encoding human MDR1 into the mouse Mdr1a locus, enabling expression of human MDR1 under the control of the mouse Mdr1a promoter.
  • the DNA sequence encoding human MDR1 is preferably a human MDR1 cDNA sequence (e.g. FIG. 75).
  • huMDR1/mdr1b /— Knock-in of a DNA sequence encoding human MDR1 into the mouse Mdr1b locus, enabling expression of human MDR1 under the control of the mouse Mdr1b promoter.
  • the DNA sequence encoding human MDR1 is preferably a human MDR1 cDNA sequence (e.g. FIG. 76). huMDR1/ Knock-in of DNA sequences encoding human MDR1 into the mdr1a —/— / mouse Mdr1a and Mdr1b loci, enabling expression of human mdr1b —/— MDR1 under the control of the mouse Mdr1a and Mdr1b promoters.
  • the DNA sequences encoding human MDR1 are preferably human MDR1 cDNA sequences (e.g. FIGS. 75 and 76).
  • the DNA sequence encoding human MPR2 is preferably a human MPR2 cDNA sequence (e.g. FIG. 77).
  • intron ‘n’ herein is meant the intron between exons ‘n’ and ‘n+1’.
  • intron 4 is that between exons 4 and 5
  • intron 5 is that between exons 5 and 6, etc.
  • the skilled person will readily be able to select an appropriate ‘panel’ of non-human animals, tissues or cells derived therefrom as disclosed herein.
  • the invention provides a tool kit from which the skilled person can select the tools required for the desired analysis.
  • the invention provides a method for investigating xenobiotic metabolism or toxicity, comprising the use of at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten types of non-human animal, tissue or cells derived therefrom, wherein each type of non-human animal, tissue or cells comprises a different genetic modification introduced using a targeting strategy or targeting vectors substantially as described herein or substantially as depicted in the Figures herein.
  • preferred targeting strategies are illustrated schematically in FIGS. 1-14 and 61 - 82 .
  • Ma et al. relates exclusively to PXR humanisation, and furthermore does not disclose or suggest many aspects of the present invention, such as the use of mixed cDNA/genomic constructs, comparison of different transgenic non-human animals, use of reporter constructs (see below) or expression of human sequences under the control of non-human animal regulatory sequences. Another drawback of the model described by Ma et al.
  • PXR humanisation is achieved by two independent genomic alterations: (i) knock-out of the endogenous PXR gene, and (ii) transgenesis with the human PXR gene at a different genomic location.
  • Preferred targeting strategies and constructs are described herein.
  • Preferred nucleic acid sequences for insertion into non-human animals, tissues or cells derived therefrom are recited in SEQ ID NOs:1-4.
  • SEQ ID NO:1 is a human PXR nucleotide sequence obtainable using a targeting vector of the invention.
  • the first three nucleotides of SEQ ID NO:1 are the translational start site from the mouse PXR gene; the start site of the human PXR gene (ctg) is not present.
  • SEQ ID NO:1 comprises sequences from introns 4 and 5 of the human PXR gene, and is obtainable using a targeting strategy as illustrated schematically in FIGS. 2 , 7 and 64 .
  • SEQ ID NO:2 is a human PXR nucleotide sequence obtainable using another targeting vector of the invention.
  • the first three nucleotides of SEQ ID NO:2 are the translational start site from the mouse PXR gene; the start site of the human PXR gene (ctg) is not present.
  • SEQ ID NO:2 comprises sequences from introns 6, 7 and 8 of the human PXR gene, and is obtainable using a targeting strategy as illustrated schematically in FIG. 61 .
  • SEQ ID NO:3 is a human PXR nucleotide sequence obtainable using a targeting vector of the invention.
  • the first three nucleotides of SEQ ID NO:3 are the translational start site from the mouse PXR gene; the start site of the human PXR gene (ctg) is not present.
  • SEQ ID NO:3 comprises sequences from introns 2, 3, 4, 5, 6, 7 and 8 of the human PXR gene, and is obtainable using a targeting strategy as illustrated schematically in FIG. 63 .
  • SEQ ID NO:4 is a human CAR nucleotide sequence obtainable using a targeting vector of the invention.
  • SEQ ID NO:4 contains a 53 bp Phi-C31 recognition site (attB53), which was inserted into intron 2 of the human CAR gene.
  • SEQ ID NO:4 comprises sequences from introns 2, 3, 4, 5, 6, 7 and 8 of the human CAR gene, and is obtainable using a strategy as illustrated schematically in FIGS. 3 , 8 and 65 .
  • the invention provides a transgenic non-human animal, tissue or cells derived therefrom, that comprises a DNA sequence as recited in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.
  • the DNA sequence is stably integrated at the locus of the endogenous equivalent gene (i.e. within the murine PXR or CAR locus).
  • the invention also provides a nucleic acid targeting vector that comprises a DNA sequence as recited in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, and which further comprises 5′ and 3′ flanking nucleic acid sequences that are homologous to 5′ and 3′ regions in the locus of the endogenous equivalent gene, and which optionally further comprises nucleic acid sequence elements that permit conditional deletion of the human DNA sequence after its integration in the locus of the endogenous equivalent gene.
  • the invention also provides a non-human animal, tissue or cells derived therefrom containing such a nucleic acid targeting vector.
  • Preferred non-human animals, tissues or cells and targeting vectors comprise a nucleic acid molecule that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identical over its entire length to a nucleic acid molecule as recited in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, or a DNA sequence that is complementary to such a nucleic acid molecule.
  • a method of introducing at least one functional human transcription factor, at least one phase-1 drug metabolising enzyme, at least one phase-2 drug-metabolising enzyme and at least one drug transporter protein into non-human cell(s) whose own endogenous equivalent genes expressing the aforesaid proteins have optionally been rendered inactive comprising introducing DNAs encoding said human transcription factor, phase-1 and 2 drug metabolising enzyme and drug transporter protein such that said human expression products remain functional, even where the cell's own endogenous genes are rendered inactive. Constructs of any one of the above-described aspects of the invention may be used.
  • endogenous non-human genes whose protein products are analogous to the protein products of the introduced human DNA sequences are deleted. This can be done preferably either by direct targeting with their human counterparts or by flanking these genes or gene clusters with recognition sites and subsequent recombinase-mediated deletion (e.g. Cre-mediated or Phi-C31-mediated deletion).
  • genes that are inserted into the transgenic model are preferably inserted at the point in the genome where the endogenous equivalent gene or gene cluster naturally occurs. This has the advantage that the context of the gene locus is retained which means that the fidelity of transcription from this site is as close as possible to the level of transcription that occurs in the wild type system.
  • the endogenous equivalent gene or genes to those that are inserted into the transgenic system optionally have been annulled.
  • Annulled is meant to include silencing or deletion or rendering inactive so that the non-human animal's endogenous equivalent gene is unable to express the gene product(s).
  • a preferable way in which to annul the expression of the endogenous equivalent gene or genes and simultaneously to insert the replacement gene at the point at which it naturally occurs is by the process of homologous recombination, described above. According to this methodology, homology arms of sequence complementary to sites in the target genome flank the insertion sequence and these are used to direct insertion of the desired human gene or genes.
  • MDR1 the drug transporter protein
  • different animal species have different MDR1 isotypes and expression profiles.
  • the mouse has two genes encoding active drug transporters (MDR1a and MDR1b), whose tissue expression is mutually exclusive.
  • MDR1 is the only functioning drug transporter of the two MDR genes present in the human (MDR1 and MDR3).
  • MDR1 should preferably replace both the endogenous MDR genes, MDR1a and MDR1b.
  • Another example can be provided by the case of CYP2D6, where there are nine genes in the mouse, corresponding to only one functional gene in humans. Replacement of the mouse gene cluster with the human gene is relatively simple though, since the latter spans less than around 40 kb of genomic sequence.
  • DNA sequences may be deleted by, for example, Cre/lox-mediated deletions. This type of deletion is suitable for deleting of large fragments of DNA (200 kb to several megabases).
  • Cre/lox-mediated deletions This type of deletion is suitable for deleting of large fragments of DNA (200 kb to several megabases).
  • the method has been described in the following papers (Li Z W, Stark G, Gotz J, Rulicke T, Gschwind M, Huber G, Muller U, Weissmann C. Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells Proc Natl Acad Sci USA. 1996 Jun. 11; 93(12):6158-62. Erratum in: Proc Natl Acad Sci USA 1996 Oct. 15; 93(21):12052 and in Su H, Wang X, Bradley A. Nested chromosomal deletions induced with retroviral vectors in mice
  • Cre/lox-mediated insertions of large fragments may also be used to insert the human DNA sequences by a method described in Call L M, Moore C S, Stetten G, Gearhart J D. A cre-lox recombination system for the targeted integration of circular yeast artificial chromosomes into embryonic stem cells. Hum Mol. Genet. 2000 Jul. 22; 9(12):1745-51.
  • the non-human transgenic animal is humanised for a drug transporter protein by the hitherto undisclosed “knock-in” approach, as shown in the schematic representation of accompanying FIGS. 1 , 2 and 3 .
  • the non-human transgenic animal of the present invention is humanised for both PXR and CAR alone or in combination, more preferably in combination.
  • the human genes are at least partially conserved within a construct.
  • the PXR construct retains the intron-exon structure between exons 4 and 6. This advantageously retains the sequence where most splice variants are observed and is conveniently located within the ligand-binding domain.
  • the preferred human PXR sequence therefore contains the cDNA of exons 1-4, the genomic sequences of intron 4, exon 5 and intron 5 and the cDNA for exons 6-9.
  • the CAR construct retains the intron-exon structure between exons 2 and 9. This advantageously retains complete genomic structure within the targeting vector and permits coverage of all splice variants of human CAR.
  • the transgenic animals are produced de novo so as to include all the aforementioned features by methods wherein, for example, cre/lox mediated deletion of large fragments of DNA (200 kb to several megabase) are achieved (Li Z W, et al. Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells Proc Natl Acad Sci USA. 1996 Jun. 11; 93(12):6158-62. Erratum in: Proc Natl Acad Sci USA 1996 Oct. 15; 93(21):12052 and in Su H et al Nested chromosomal deletions induced with retroviral vectors in mice. Nat.
  • the transgenic non-human animal of the present invention is produced by crossing.
  • the animal of WO2004/007708 might be crossed with those transgenic animals that have been humanised with PXR and/or CAR and include further modifications with respect to phase-2 drug metabolising enzymes and drug transporter protein in either transgenic strain of the non-human animal.
  • transgenic non-human animal is produced de novo so as to include all of the aforementioned features, by the methods as hereinafter disclosed.
  • the present invention provides a non-human transgenic animal that mimics the human mechanisms of metabolism, disposition or toxicity of drugs or other xenobiotic compounds on a non-human animal cell by introducing into a non-human animal cell one or more human DNA sequences comprising coding and regulatory sequences necessary to reproduce the regulation and function of one or more proteins responsible for human metabolism, disposition or toxicity of drugs or other xenobiotic compounds where the said non-human animal cell has undergone deletion of endogenous genes encoding proteins whose functions are analogous to those encoded by the introduced human DNA sequences so that the non-human animal cell can be used as a model system for determining the metabolism, disposition or toxicity of drugs or other xenobiotic compounds in a homologous human cell.
  • CYP3A4 gene expression levels may vary as much as 60 times between individuals, and in any individual may also vary over time. This is partly because of inherent genetic differences, but more importantly due to variability in exposure to drugs, toxins, food products and other environmental variables.
  • the system is an adaptive response system which will only keep high enzyme levels for as long as they are needed. Any other implementation would be wasteful. This means that it is not generally appropriate, in any test system, merely to test the effect of a particular drug concentration at one level of CYP3A4.
  • CYP2D6 protein which plays a major role in the metabolism of neuroleptic drugs (e.g. anti-depressants and drugs used for treatment of schizophrenia), and is thus of significant importance.
  • Pharmaceutical companies are reluctant to back a drug that is metabolised by CYP2D6 and therefore need to know as soon as possible during development of any drug, whether or not it has a CYP2D6 liability.
  • This gene shows variation between individuals, and in fact expression is absent in around 6% of Caucasian individuals. It would be of immense benefit to be able to study the metabolism of drugs, particularly of anti-depressants, in environments of both high and low CYP2D6 levels.
  • P450 levels either as single genes or a multiple genes and preferably as clusters of genes, may be raised to artificially high levels in order to test for potentially carcinogenic effects of metabolites. At physiologically normal levels, the effects of such metabolites might not be evident.
  • the marked species difference in carcinogenicity of compounds between rodents and man result in the main from the different rates of generation of toxic or mutagenic metabolites, along with other differences in pharmacokinetics and distribution.
  • the ability to increase gene levels in entire clusters is important as it retains the substrate crosstalk between the different proteins expressed by the genes in the cluster.
  • Bespoke systems of this type may also be exploited to investigate disease.
  • An example is provided by Gilbert syndrome, a phenomenon caused by a polymorphism in the UGT1A1 gene implicated in drug metabolism.
  • a transgenic model animal may incorporate the polymorphism-containing gene in order to allow this syndrome to be evaluated.
  • a host cell transfected with a nucleic acid construct(s) according to any one of the previous aspects of the invention.
  • the cell type is preferably of human or non-human mammalian origin but may also be of other animal, plant, yeast or bacterial origin.
  • transgenic non-human animal in which the cells of the non-human animal express the protein(s) encoded by the nucleic acid construct(s) according to any one of the previous aspects of the invention.
  • the transgenic animal is preferably a mouse, because of currently available technology, but may be another mammalian species, for example another rodent, for instance a rat or a guinea pig, or another species such as rabbit, pig, or a canine or feline, or an ungulate species such as ovine, equine, bovine, or a non-mammalian animal species.
  • the cell or non-human animal may be subjected to further transgenesis, in which the transgenesis is the introduction of an additional gene or genes or protein-encoding nucleic acid sequence or sequences.
  • the transgenesis may be transient or stable transfection of a cell or a cell line, an episomal expression system in a cell or a cell line, or preparation of a transgenic non-human animal by pronuclear microinjection, through recombination events in non-embryonic stem (ES) cells, random transgenesis in non-human embryonic stems (ES) cells or by transfection of a cell whose nucleus is to be used as a donor nucleus in a nuclear transfer cloning procedure.
  • ES non-embryonic stem
  • ES non-human embryonic stems
  • Methods of preparing a transgenic cell or cell line, or a transgenic non-human animal in which the method comprises transient or stable transfection of a cell or a cell line, expression of an episomal expression system in a cell or cell line, or pronuclear microinjection, recombination events in ES cells, or other cell line or by transfection of a cell line which may be differentiated down different developmental pathways and whose nucleus is to be used as the donor for nuclear transfer; wherein expression of an additional nucleic acid sequence or construct is used to screen for transfection or transgenesis in accordance with the previous aspects of the invention.
  • Examples include use of selectable markers conferring resistance to antibiotics added to the growth medium of cells, for instance neomycin resistance marker conferring resistance to G418. Further examples involve detection using nucleic acid sequences that are of complementary sequence and which will hybridise with, or a component of, the nucleic acid sequence in accordance with the previous aspects of the invention. Examples would include Southern blot analysis, northern blot analysis and PCR.
  • Non-human animal cell or transgenic non-human animals produced by the method of the invention can be used as model systems for determining the metabolism of drugs or other xenobiotic compounds in a human.
  • transgenic animal, tissues and/or cells derived therefrom as hereinbefore described that have been modified to contain and express DNA encoding at least one functional human transcription factor, at least one phase-1 drug metabolising enzyme, at least one phase-2 drug-metabolising enzyme and at least one drug transporter protein so as to investigate xenobiotic metabolism or toxicity in said a transgenic animal, tissues and/or cells derived therefrom or other properties or functions of the introduced human proteins such as metabolism and/or biosynthesis of endogenous compounds.
  • the system of the present invention allows function and regulation of human mechanisms of xenobiotic metabolism, disposition and toxicity to be studied in any tissue or cell type, for instance gastrointestinal tract, blood-brain barrier, liver, kidney in a single animal, tissue or cell derived therefrom.
  • the system of the present invention may be applied to study effects of human metabolism, disposition or toxicity on anti-tumour effects of a drug in an animal xenograft experiment by expressing humanised metabolic pathways in a non-human grafted tumour cell line and/or in the host animal.
  • the present invention also, advantageously provides non-human animal cells and transgenic non-human animals incorporating introduced reporter genes so that such cells or animals can be used to determine indications of pathways of metabolism of drugs or other xenobiotic compounds in a human cell by convenient assay of the products of reporter gene expression.
  • the cells or animals can be used to determine regulation of genes and also give indications of the likely mechanism and metabolism of drugs or other xenobiotic compounds in an homologous human cell by assaying expression of the reporter gene DNA sequence.
  • the cells or animals can also be used to give indications of the extent of metabolism of drugs or other xenobiotic compounds. For example, analysis of the distribution of reporter gene expression within any particular tissue allows the extent of induction of gene expression to be monitored in response to a particular drug compound.
  • a non-human animal, tissue or cells derived therefrom incorporating a promoter linked transcriptionally to a human DNA sequence encoding:
  • the promoter of the transcription factor and/or phase 1 and/or phase 2 drug-metabolising enzyme and/or drug transporter protein may thus be linked to a reporter which allows monitoring for the relative regulation of at least one enzyme involved in drug/xenobiotic disposition.
  • a reporter which allows monitoring for the relative regulation of at least one enzyme involved in drug/xenobiotic disposition.
  • Such an embodiment advantageously allows not only for relative regulation of the enzymes but regulation in both a tissue-specific manner in the transgenic animal or in the whole animal itself in a non-invasive manner as well as the extent and potency of gene induction.
  • Reporters may be linked to the promoters of two or more of (i), (ii), (iii) or (iv) listed above.
  • Reporter genes are nucleic acid sequences encoding directly or indirectly assayable proteins. They are used to replace other coding regions whose protein products are unsuitable or not amenable to the assay envisaged.
  • Suitable reporter genes that are known in the art and may be used in the present invention are selected from those genes encoding proteins including but not limited to: chloramphenicol-acetyltransferase, ⁇ -galactosidase, ⁇ -glucuronidase, luciferase, beta-galactosidase, green fluorescent protein, secreted alkaline phosphatase (SEAP), major urinary protein (MUP) or human chorionic gonadotrophin (hCG).
  • SEAP secreted alkaline phosphatase
  • MUP major urinary protein
  • hCG human chorionic gonadotrophin
  • the promoters that are preferred targets for linkage to reporter genes are PXR, CAR, CYP3A4, Cyp3a11, CYP2C9, CYP2C19, CYP2B6, CYP2D6, UGT1A, MRP2 and MDR1.
  • the reporter embodiments of the invention can be used in comparative methods.
  • the skilled person will readily be able to select an appropriate ‘panel’ of reporter non-human animals, tissues or cells derived therefrom as disclosed herein.
  • the type and number of non-human animals, tissues or cells required for comparison will depend on the type of analysis required (e.g. depending on the drug metabolism pathway of interest and/or the drug of interest).
  • the invention provides transgenic non-human animals, tissues or cells derived therefrom of various reporter genotypes (see elsewhere herein).
  • the invention provides a tool kit from which the skilled person can select the tools required for the desired analysis.
  • the invention provides a method for investigating xenobiotic metabolism or toxicity, comprising the use of:
  • the invention also provides a method for investigating xenobiotic metabolism or toxicity, comprising the use of at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten types of non-human animal, tissue or cells derived therefrom, wherein each type of non-human animal, tissue or cells comprises a different endogenous regulatory sequence (e.g. a mouse or human promoter) operatively linked to a DNA sequence whose expression can conveniently be measured by assay of transcription and/or translation products (i.e. a reporter sequence), and wherein each endogenous regulatory sequence is a regulatory sequence normally associated with a gene encoding a protein involved in drug metabolism.
  • a different endogenous regulatory sequence e.g. a mouse or human promoter
  • each endogenous regulatory sequence is a regulatory sequence normally associated with a gene encoding a protein involved in drug metabolism.
  • the DNA sequence whose expression can conveniently be measured by assay of transcription and/or translation products will be the same in the different non-human animals, tissues or cells, but in other embodiments different reporter sequences are used.
  • transgenic non-human animals are compared may involve administering the same drug at the same dose to the different types of non-human animal (i.e. to different types of reporter) and comparing the metabolism or toxicity of that drug between the different animals.
  • transgenic non-human animals, tissues and cells of the invention have a genotype as specified in the following list.
  • the prefix “hu” refers to humanisation of the relevant endogenous non-human animal gene.
  • the prefix “r” denotes that an endogenous regulatory sequence (e.g. a mouse or human promoter) for the relevant gene is operatively linked to a DNA sequence whose expression can conveniently be measured by assay of transcription or translation products (i.e. a reporter sequence).
  • transgenic non-human animals, tissues and cells of the invention incorporate a combination of two or more of the genotypes described herein above, some examples of which are specified in the following list, wherein the symbol “/” indicates a combination of genetic modifications.
  • Transgenic non-human animals, tissues and cells having a complex genotype as listed above are particularly preferred, because the drug metabolism pathways in those non-human animals, tissues and cells more closely resemble the in vivo situation in humans.
  • the invention provides a method of generating a non-human animal cell comprising a reporter construct as described herein using a targeting strategy or vector substantially as described herein or substantially as depicted in the Figures herein.
  • the invention provides a transgenic mouse, tissue or cells derived therefrom comprising one or more of the following genetic manipulations:
  • rCYP2B6 Expression of a reporter gene under the control of a human CYP2B6 promoter sequence.
  • a reporter gene and a human promoter sequence are inserted into the mouse Cyp2b6 locus.
  • the reporter gene is a LacZ reporter gene (e.g. FIG. 78).
  • a reporter gene and a human promoter sequence are inserted into the mouse Cyp2d6 locus.
  • the reporter gene is a ZsYellow reporter gene (e.g. FIG. 79).
  • rCYP3A4 Expression of a reporter gene under the control of a human CYP3A4 promoter sequence.
  • a reporter gene and a human promoter sequence are inserted into the mouse Cyp3a4 locus.
  • the reporter gene is a hCG-ZsGreen reporter gene (e.g. FIG. 80).
  • rCyp3a11 Expression of a reporter gene under the control of a mouse Cyp3a11 promoter sequence.
  • a reporter gene is inserted into the mouse Cyp3a11 locus.
  • the reporter gene is a Firefly luciferase (e.g. FIG. 81) or a ZsGreen (e.g. FIG. 70) reporter gene.
  • the human MDR1 promoter sequence comprises both upstream and downstream promoter sequences.
  • a reporter gene and a human promoter sequence are inserted into the mouse Rosa26 locus.
  • the reporter gene is a Firefly luciferase reporter gene (e.g. FIG. 82). Further details of the preferred reporter strategies and constructs are provided in the Examples and Figures herein.
  • Animals, tissues and cells according to these aspects of the invention allow very useful elements of the process of gene regulation in drug metabolism to be elucidated.
  • PXR is known to be of great significance in the transcriptional control of the CYP3A4 gene, there are likely to be other important active mechanisms.
  • Exposing a CYP3A4 reporter animal or cell to a drug compound in either a humanised PXR or a PXR null background would be useful in exploring other ways of regulating CYP3A4 than by way of PXR.
  • Another case of interest would be to expose an mdr1 reporter animal or cell to a drug compound in both a humanised PXR and PXR null background to detect aspects of mdr1 expression that are independent of PXR regulation.
  • animals, tissues and cells according to this aspect of the invention may comprise a promoter linked transcriptionally to a human DNA sequence encoding a phase-1 drug-metabolising enzyme; a DNA sequence encoding a phase-2 drug-metabolising enzyme; and/or a DNA sequence encoding a drug transporter protein in a null background for PXR, CAR or any other transcription factor.
  • null background is meant that the gene or genes have been annulled, according to the definition provided above.
  • Such animals, cells, or tissues might be compared under similar conditions (for example, in the presence and absence of a drug or drugs) to in a humanised PXR or CAR background.
  • animals, tissues and cells according to this aspect of the invention may comprise a promoter linked transcriptionally to a human DNA sequence encoding a phase-1 drug-metabolising enzyme; a DNA sequence encoding a phase-2 drug-metabolising enzyme; and/or a DNA sequence encoding a drug transporter protein in a humanised background for a transcription factor.
  • a transcription factor may be PXR alone, CAR alone, PXR and CAR or any other single transcription factor or combination of transcription factors described herein.
  • a reporter gene is fused to the translational start site of the corresponding human gene whose promoter is to be investigated.
  • the transcript of the reporter gene may not be terminated by a polyA motif, but the constructs are designed such that the endogenous polyA motif is potentially used. These constructs are therefore dependent on a correct splicing of the exons 3′ to the reporter (see FIG. 12 ).
  • the transcript of the reporter gene is preferably terminated by a polyA motif linked to the reporter gene with a synthetic intron (see FIG. 13 ).
  • the transcript of the reporter gene is preferably terminated by a polyA motif without an additional intron (see FIG. 14 ).
  • a non-human animal, tissue or cells derived therefrom incorporating at least one human DNA sequence encoding at least one transcription factor under control of a transcription factor promoter and whose endogenous equivalent genes have optionally been annulled, the non-human animal, tissue or cells further incorporating a promoter linked transcriptionally to a human DNA sequence encoding:
  • the non-human animal, and tissues or cells of this aspect of the invention may incorporate a promoter linked transcriptionally to a DNA sequence encoding a phase-1 drug-metabolising enzyme and a DNA sequence encoding a phase-2 drug-metabolising enzyme.
  • the non-human animal, and tissues or cells may incorporate a promoter linked transcriptionally to a DNA sequence encoding a phase-1 drug-metabolising enzyme and a DNA sequence encoding a drug transporter protein.
  • the non-human animal, and tissues or cells may incorporate a promoter linked transcriptionally to a DNA sequence encoding a phase-2 drug-metabolising enzyme and a DNA sequence encoding a drug transporter protein. Examples of suitable phase-1 drug-metabolising enzymes, phase-2 drug-metabolising enzymes and drug transporter proteins are described herein.
  • the promoter activity of the mdr1 gene may be investigated.
  • animals, tissues and cells may comprise a promoter linked transcriptionally to a human DNA sequence encoding a transcription factor, a promoter linked transcriptionally to a human DNA sequence encoding a phase-1 drug-metabolising enzyme; and/or a promoter linked transcriptionally to a DNA sequence encoding a phase-2 drug-metabolising enzyme in a humanised or null background for mdr1.
  • a non-human animal, tissue or cells derived therefrom incorporating at least one human DNA sequence encoding at least one drug transporter protein under control of a drug transporter promoter and whose endogenous equivalent genes have optionally been annulled, the non-human animal, tissue or cells further incorporating a promoter linked transcriptionally to a human DNA sequence encoding:
  • the non-human animal, and tissues or cells of this aspect of the invention may incorporate a promoter linked transcriptionally to a DNA sequence encoding a phase-1 drug-metabolising enzyme and a DNA sequence encoding a phase-2 drug-metabolising enzyme.
  • the non-human animal, and tissues or cells may incorporate a promoter linked transcriptionally to a DNA sequence encoding a phase-1 drug-metabolising enzyme and a DNA sequence encoding a transcription factor.
  • the non-human animal, and tissues or cells may incorporate a promoter linked transcriptionally to a DNA sequence encoding a phase-2 drug-metabolising enzyme and a DNA sequence encoding a transcription factor. Examples of suitable phase-1 drug-metabolising enzymes, phase-2 drug-metabolising enzymes and transcription factor proteins are described herein.
  • nucleic acid construct comprising a targeting vector substantially as depicted in any of FIGS. 1-14 and 61 - 82 .
  • the construct further includes for the humanisation and corresponding knock-out of at least one phase-1 drug metabolising enzyme, at least one phase-2 drug-metabolising enzyme and at least one drug transporter protein in either the same construct or further independent constructs.
  • an animal cell is produced by any one of the above-described aspects of the invention.
  • at least one human regulatory DNA sequence associated with the gene encoding a protein responsible for determining the human metabolism, disposition, distribution or toxicity of drugs or other xenobiotic compounds is operatively linked to a DNA sequence whose expression can conveniently be measured by assay of transcription or translation products to produce a reporter gene DNA sequence which is introduced into the non-human animal cell.
  • This embodiment provides linkage with one or more reporter sequences such as human chorionic gonadotrophin (hCG).
  • the animals, tissues and cells of the present invention may be used to determine how a drug compound is metabolised by a human.
  • a drug compound modulates the activity or expression levels of a transcription factor, a drug metabolising enzyme or a drug transporter protein.
  • a drug compound influences the duration of expression of a transcription factor, a drug metabolising enzyme or a drug transporter protein.
  • a physiological effect may be, for example, a disease condition (such as biliary necrosis) or a toxic side-effect.
  • the rate of metabolism may be determined by measuring the toxicity or activity mediated by the administration of the compound, measuring the half-life of the compound, or measuring the level of a drug metabolising enzyme.
  • the rate of metabolism of the compound may be measured as the rate of formation of the oxidized product or the formation of a subsequent product generated from the oxidized intermediate.
  • the rate of metabolism may be represented as the half-life or rate of disappearance of the initial compound or as the change in toxicity or activity of the initial compound or a metabolite generated from the initial compound.
  • the half-life may be measured by determining the amount of the drug compound present in samples taken at various time points.
  • the amount of the drug compound may be quantified using standard methods such as high-performance liquid chromatography, mass spectrometry, western blot analysis using compound specific antibodies, or any other appropriate method.
  • a drug compound is metabolised to a toxic or carcinogenic metabolite, for example, by measuring its covalent binding to tissues, proteins or DNA or by measuring glutathione depletion.
  • measurements of the type described above are performed at more than 1, 3, 5, 10 or more time points after administration of the drug compound.
  • further aspects of the invention relate to screening methods that are provided to determine the effect of a drug compound on the activity or expression level of a transcription factor, a drug metabolising enzyme or a drug transporter protein.
  • Such methods involve administering a drug compound to a transgenic animal according to any one of the aspects of the invention described above, or a tissue or cell derived therefrom.
  • the screening step may involve measuring the induction of a gene coding for a transcription factor, a drug metabolising enzyme or a drug transporter protein.
  • the screening step may involve measuring the level of expression of a transcription factor, a drug metabolising enzyme or a drug transporter protein or the duration of such expression.
  • the screening step may involve measuring the distribution of expression of a transcription factor, a drug metabolising enzyme or a drug transporter protein.
  • the assay can be performed in the presence and absence of the drug compound to ascertain differences in distribution, metabolism and toxicity.
  • the effects of the drug compound in the presence and absence of a particular gene or genes can be ascertained by evaluating the effects of the drug compound on different transgenic animals, cells or tissues. For example, the effects of the drug compound could be evaluated between an animal with a null background and an animal humanised for the gene or genes of interest (e.g. PXR, CAR, MDR1, a phase I metabolising enzyme or a phase 2 metabolising enzyme).
  • the invention provides methods for investigating xenobiotic metabolism or toxicity as described herein, comprising administering a drug compound to 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more of the non-human animals, tissues or cells described herein.
  • such methods further include a step of comparing the experimental results obtained for different non-human animals, tissues or cells.
  • More than one drug compound may be administered.
  • a drug compound is determined to activate the CAR transcription factor if the compound mediates induction of the CAR gene.
  • a CAR receptor inverse agonist such as clotrimazole can also administered to an animal expressing the human CAR receptor as a control.
  • Assays according to further aspects of the invention may provide a screening method for determining whether the metabolism of a first drug compound is modulated by a second drug compound.
  • This method involves administering the first compound in the presence and absence of the second compound to a transgenic animal according to any one of the above-described aspects of the invention, or a tissue or cell derived therefrom, and monitoring for a phenotypic effect.
  • the screening step may involve measuring the induction of a gene, the level, duration or distribution of expression, of a transcription factor, a drug metabolising enzyme or a drug transporter protein.
  • the second compound is determined to modulate the metabolism of the first compound if the second compound effects a change in any one of these tested factors. For example, a physiological effect may be assayed by measuring the toxicity or activity mediated by the administration of the first compound or measuring the half-life of the first drug compound.
  • assays may be used to facilitate the identification of analogs of a drug compound that have reduced or undetectable ability to activate or induce expression of a particular protein, and thus are expected to have fewer side-effects or a longer half-life in vivo.
  • FIG. 1 shows a schematic representation of humanisation and knock out of PXR/CAR
  • FIG. 2 shows a schematic representation of a composite cDNA with genomic sequences for the PXR humanisation strategy
  • FIG. 3 shows a schematic representation of a composite cDNA with genomic sequences for the CAR humanisation strategy
  • FIG. 4 shows a possible mouse mdr1a targeting vector
  • FIG. 5 shows a possible mouse mdr1b targeting vector
  • FIG. 6 shows a possible construct for MRP2 humanisation
  • FIG. 7 shows a possible targeting strategy for PXR humanisation
  • FIG. 8 shows a possible targeting strategy for CAR humanisation
  • FIG. 9 shows a possible strategy for CYP3A4 humanisation
  • FIG. 10 shows a possible strategy for CYP2C9 humanisation
  • FIG. 11 shows a possible overall strategy for cluster exchange
  • FIG. 12 shows a possible overall strategy for reporter constructs
  • FIG. 13 shows a possible reporter project strategy for CYP2D6 and CYP2B6
  • FIG. 14 shows a possible reporter project strategy for MDR1
  • FIG. 15 shows an example of a PXR typing PCR
  • FIG. 16 shows Taqman typing of wild type and transgenic mice. All probes and primers used were pre-optimised TaqMan® Genomic Assay kits, which were purchased from Applied Biosystems. All assays used were inventoried by Applied Biosystems. Shown are the results from TaqMan analysis of liver (A, B) and small intestine (C, D) of nine wild-type and four hPXR mice, using assays specific for the mouse PXR mRNA transcript (A, C) or the human PXR mRNA transcript (B, D);
  • FIG. 17 shows RT-PCR of huPXR transcripts in transgenic mice
  • FIG. 18 shows Western blotting of PXR protein from wild type and hPXR mice. Proteins from the livers of treated wild-type and huPXR mice were probed with an antibody specific for the PXR protein. The standard (+ve) was a his-tagged murine PXR;
  • FIG. 19 shows Western blotting of Cyp3a and Cyp2b induction by rifampicin.
  • Microsomal proteins from the livers of rifampicin treated wild-type and huPXR mice were probed with antibodies for the Cyp 3a11 protein (top panel) and Cyp 2b10 (bottom panel);
  • FIG. 20 shows enzyme activity assays of Cyp3a and Cyp2b10 induction by rifampicin (100 mg/kg). Shown are the results from enzyme activity assays on liver microsomes using activity of pentoxyresorufin-O-deethylation (PROD) which is attributed to expression level of Cyp 2b10 and the activity of 7-benzyloxyquinoline (BQ) which is attributed to expression level of Cyp 3a;
  • PROD pentoxyresorufin-O-deethylation
  • BQ 7-benzyloxyquinoline
  • FIG. 21 shows enzyme activity assays in liver microsomes following induction by rifampicin (3 mg/kg and 10 mg/kg)—7-benzyloxyquinoline. Shown are the results from enzyme activity assays on liver microsomes using the activity 7-benzyloxyquinoline;
  • FIG. 22 shows enzyme activity assays in liver microsomes following induction by rifampicin (3 mg/kg and 10 mg/kg)—6-beta-hydroxylation of testosterone (p ⁇ 0.01);
  • FIG. 23 shows enzyme activity assays in liver microsomes following induction by rifampicin (3 mg/kg and 10 mg/kg)—16-beta-hydroxylation of testosterone (p ⁇ 0.05);
  • FIG. 24 shows enzyme activity assays in liver microsomes following induction by TCPOBOB (0.3 mg/kg and 1.0 mg/kg)—7-alpha-hydroxylation of testosterone which was constitutively higher in the huPXR animals relative to the wild types;
  • FIG. 25 shows enzyme activity assays in liver microsomes following induction by TCPOBOB (0.3 mg/kg and 1.0 mg/kg)—6-beta-hydroxylation of testosterone;
  • FIG. 26 shows enzyme activity assays in liver microsomes following induction by TCPOBOB (0.3 mg/kg and 1.0 mg/kg)—16-alpha-hydroxylation of testosterone. These demonstrate that this activity was significantly induced in wild type animals (p ⁇ 0.05) but not in huPXR animals;
  • FIG. 27 shows enzyme activity assays in liver microsomes following induction by TCPOBOB (0.3 mg/kg and 1.0 mg/kg)—16-beta-hydroxylation of testosterone. These demonstrate that this activity was much more marked in wild type than in huPXR animals;
  • FIG. 28 shows PCR confirmation in two double homozygous PXR/CAR humanised mice that the murine PXR gene has been exchanged for the human counterpart.
  • FIG. 29 shows a Cyp3a11 induction profile in response to rifampicin treatment in wild-type and huPXR mice.
  • FIG. 30 shows a Cyp3a11 induction profile in response to dexamethasone treatment in wild-type and huPXR mice.
  • FIG. 31 shows the results of TaqMan® analysis of PXR mRNA in the livers of wild-type and koPXR mice.
  • FIG. 32 shows effects of rifampicin administration on Cyp3a11 expression and activity in wild-type, huPXR or koPXR mice.
  • FIG. 33 shows that rifampicin does not induce Cyp2b10 expression in wild-type and huPXR mice.
  • FIG. 34 shows effects of dexamethasone administration on the expression and activity of Cyp3a11 and Cyp2b10 in wild-type, huPXR and koPXR mice.
  • FIG. 35 shows effects of dexamethasone administration on Cyp3a11 expression and activity in wild-type, koPXR and huPXR mice.
  • FIG. 36 shows species-specific differences in dexamethasone mediated hepatotoxicity in huPXR and koPXR mice.
  • FIG. 37 shows the liver/body weight ratios of wild-type, huPXR and koPXR mice following administration of either 60 mg/kg rifampicin or dexamethasone.
  • FIG. 38 shows an overview of the effects of rifampicin and dexamethasone on Cyp3a11 and Cyp2b10 expression in wild-type, huPXR and koPXR mice.
  • a medium increase compared to vehicle-treated mice is denoted by ‘++’
  • a strong increase compared to vehicle-treated mice is denoted by ‘+++’
  • no change compared to vehicle-treated mice is denoted by ‘NC’.
  • FIG. 39 shows the results of TaqMan® analysis of CAR mRNA in the livers and intestines of untreated wild-type and koCAR mice, demonstrating that basal expression of CAR mRNA was completely lost in the koCAR mouse.
  • FIG. 40 shows hepatotoxicity data for wild-type, koCAR and koPXR mice, after treatment with dexamethasone or phenobarbital.
  • FIG. 41 shows effects of dexamethasone and phenobarbital administration on the livers of koCAR and koPXR mice.
  • FIG. 42 shows effects of dexamethasone and phenobarbital administration on the guts and livers of koCAR and koPXR mice.
  • FIG. 43 shows densitometric quantification of Western blot bands obtained from TCPOBOP-treated livers of wild-type and koCAR mice.
  • FIG. 44 shows that human CAR mRNA, but not mouse CAR mRNA, is expressed in the livers of huCAR mice (TaqMan® analysis).
  • FIG. 45 shows further results of CAR mRNA analysis in wild-type and huCAR mice by TaqMan® analysis, for liver and small intestine.
  • FIG. 46 shows CITCO hepatotoxicity data for wild-type and huCAR mice.
  • FIG. 47 shows effects of CITCO in wild-type and huCAR mice.
  • FIG. 48 is a schematic illustration of the rationale for screening assays for PXR and CAR activity.
  • FIG. 49 shows effects of TCPOBOP on Cyp2b10 expression and activity in wild-type and huCAR mice.
  • FIG. 50 shows a comparison of the effects of CITCO and TCPOBOP in wild-type and huCAR mice.
  • FIG. 51 shows effects of phenobarbital treatment on Cyp2b10 expression and activity in wild-type and huCAR mice.
  • FIG. 52 shows effects of dexamethasone treatment on Cyp2b10 expression and activity in wild-type and huCAR mice.
  • FIG. 53 shows effects of treatment with CITCO or TCPOBOP on Cyp2b10 expression and activity in wild-type, huCAR, koCAR, huPXR and koPXR mice.
  • FIG. 54 shows effects of TCPOBOP treatment on Cyp3a11 expression and activity in wild-type and huCAR mice.
  • FIG. 55 provides an overview of the effects of selected drug-metabolism inducers on the expression of Cyp3a11 and Cyp2b10 in mouse and human.
  • FIG. 56 illustrates species-specific differences in the hyperplastic response to CAR activators between wild-type and huCAR mice.
  • FIG. 57 shows PXR and CAR mRNA levels in huPXR/huCAR double-humanised mice and in wild-type, huPXR and huCAR mice. Human PXR and CAR mRNA expression is maintained in double humanised mice.
  • FIG. 58 shows effects of rifampicin and phenobarbital treatment in double-humanised huPXR/huCAR, wild-type, huPXR and huCAR mice, and basal levels of Cyp2b10 and Cyp3a11 protein in huPXR/huCAR, wild-type, huPXR and huCAR mice.
  • FIG. 59 shows tissue samples from wild-type and rCyp2B6/huCAR reporter mice, illustrating the spatial expression pattern for Cyp2B6 in liver microsomes.
  • FIG. 60 shows tissue samples from wild-type and rCyp2D6/huPXR reporter mice, illustrating the spatial expression pattern for Cyp2D6 in liver microsomes.
  • FIG. 61 shows a further possible targeting strategy for PXR humanisation (to produce mice of genotype huPXR).
  • FIG. 62 shows a schematic map of a targeting vector useful for PXR humanisation.
  • FIG. 63 shows a further possible targeting strategy for PXR humanisation (to produce mice of genotype huPXR).
  • FIG. 64 shows a possible targeting strategy for PXR humanisation and knock-out (to produce mice of genotype huPXR and koPXR).
  • FIG. 65 shows a possible targeting strategy for CAR humanisation and knock-out (to produce mice of genotype huCAR and koCAR).
  • FIG. 66 shows a schematic map of a targeting vector useful for CAR humanisation and knock-out.
  • FIG. 67 shows a possible targeting strategy for the PPAR ⁇ humanisation and knock-out in mice (to produce mice of genotype huPPAR ⁇ and koPPAR ⁇ ).
  • FIG. 68 shows a possible targeting strategy for AhR humanisation and knock-out in mice (to produce mice of genotype huAhR and koAhR).
  • FIG. 69 shows a possible targeting strategy for CYP3A4 humanisation in mice (to produce mice of genotype huCYP3A4).
  • FIG. 70 shows a possible targeting strategy for Cyp3a11 knock-out in mice (to produce mice of genotype koCyp3a11), which at the same time produces a reporter construct (of the genotype rCyp3a11).
  • FIG. 71 panels A-C show a possible targeting strategy for the generation of mice humanised with respect to the CYP3A cluster or wherein the CYP3A cluster is knocked out (to produce mice of genotype huCYP3A cluster and koCYP3A cluster).
  • FIG. 71A shows a strategy for 5′ targeting of the mouse Cyp3a cluster.
  • FIG. 71B shows a strategy for 3′ targeting of the mouse Cyp3a cluster (at the Cyp3a25 locus).
  • FIG. 71C shows an overview of a cluster exchange strategy.
  • FIG. 72 shows a possible targeting strategy for CYP2C9 humanisation in mice (to produce mice of genotype huCYP2C9).
  • FIG. 73 panels A-C show a possible targeting strategy for the generation of mice humanised with respect to the CYP2C cluster or wherein the CYP2C cluster is knocked out (to produce mice of genotypes huCYP2C cluster and koCYP2C cluster).
  • FIG. 73A shows a strategy for 5′ targeting of the mouse Cyp2c cluster.
  • FIG. 73B shows a strategy for 3′ targeting of the mouse Cyp2c cluster.
  • FIG. 73C shows an overview of a cluster exchange strategy.
  • FIG. 74 panels A-C show a possible targeting strategy for the generation of mice humanised with respect to the Ugt1 cluster or wherein the Ugt1 cluster is knocked out (to produce mice of genotypes huUGT cluster and koUGT cluster).
  • FIG. 74A shows a strategy for 5′ targeting of the mouse UGT cluster.
  • FIG. 74B shows a strategy for 3′ targeting of the mouse UGT cluster.
  • FIG. 74C shows an overview of a cluster exchange strategy.
  • FIG. 75 shows a possible targeting strategy for MDR1 humanisation at the mouse Mdr1a locus (to produce mice of genotype huMDR1/mdr1a ⁇ / ⁇ ).
  • FIG. 76 shows a possible targeting strategy for MDR1 humanisation at the mouse Mdr1b locus (to produce mice of genotype huMDR1/mdr1b ⁇ / ⁇ ).
  • FIG. 77 shows a possible targeting strategy for MRP2 humanisation (to produce mice of genotype huMRP2).
  • FIG. 78 shows a possible targeting strategy for the generation of a CYP2B6 reporter system in mice (to produce mice of genotype rCYP2B6).
  • FIG. 79 shows a possible targeting strategy for the generation of a CYP2D6 reporter system in mice (to produce mice of genotype rCYP2D6).
  • FIG. 80 shows a possible targeting strategy for the generation of a CYP3A4 reporter system in mice (to produce mice of genotype rCYP3A4 mice).
  • FIG. 81 shows a possible targeting strategy for the generation of a Cyp3a11 reporter system in mice (to produce mice of genotype rCyp3a11).
  • FIG. 82 shows a possible targeting strategy for the generation of a MDR1 reporter system in mice (to produce mice of genotype rMDR1).
  • FIG. 83 shows an overview of the effects of various inducing agents on PXR and CAR target genes in the livers of wild-type, huPXR, koPXR and huCAR mice.
  • a slight increase in expression compared to vehicle-treated mice of the same strain is denoted by a ‘+’
  • a medium increase in expression compared to vehicle-treated mice of the same strain is denoted by a ‘++’
  • a strong increase in expression compared to vehicle-treated mice of the same strain is denoted by a ‘+++’
  • no change compared to vehicle-treated mice of the same strain is denoted by ‘NC’.
  • the method provides for the humanisation of mice for PXR and CAR alone or as a double humanised form for each of the genes (see FIG. 1 ).
  • ES cells embryo stem cells
  • PXR/CAR double humanised ES cells which are usable for subsequent modifications with human DNA sequence encoding a phase-1 or 2 drug-metabolising enzyme human DNA sequences encoding a drug transporter protein.
  • PhiC31 recombination sites enabled us to knock out both genes by crossing the humanised animal to a Phi31 deleter strain.
  • genomic structures of human genes are at least partially conserved within the construct of the present invention.
  • PXR we have used a composite construct of cDNA and genomic sequences (see FIG. 2 ). Due to the large size of more than 35 kb of the human PXR gene, we kept the intron-exon structure solely between 4 and 6, since most splice variants are observed in this genomic region since it is located within the ligand-binding domain.
  • the relatively small size of the human CAR which comprises roughly 7 kb from exon 2-9, enabled us to retain the complete genomic structure in our targeting vector ( FIG. 3 ).
  • the ES cells comprising humanised PXR and/or CAR can be further modified with human genes that regulate drug metabolising enzymes (phase1 and 2) and/or drug transporter proteins. It will be possible to cross the animals cells with humanised PXR/CAR with the HRN mouse below or to create a de novo non-human transgenic animal with all of the aforementioned criteria.
  • CPR cytochrome P450 reductase
  • An adenoviral vector may be used to introduce the human P450/CPR combination to HRNTM cells.
  • germ line transgenic animals incorporating the same transgenes can be produced. This is achieved by first generating transgenic mice incorporating the selected CYP3A4/CPR humanisation transgenes and then crossbreeding these with HRNTM mice to produce CYP3A4-humanised animals. Production of CYP3A4/CPR transgenic mice is achieved by using targeted transfection of embryonic stem cells and subsequent blastocyst injection. Crossbreeding of CYP3A4/CPR transgenics with HRNTM to produce P450-humanised animals may be used for the production of multi-P450-humanised mice.
  • embryonic stem cells may be produced where the CPR gene is flanked by loxP sites and where expression sequences for targeted human P450(s) and CPR or for human P450-CPR fusion protein(s) have been introduced. Animals derived from such embryonic stem cells may then be crossbred with various animal strains in which cre recombinase is expressed under the control of different promoters to produce offspring P450-humanised in different tissues or under different induction conditions, depending on the tissue specificity or inducibility of the promoter controlling cre recombinase expression.
  • Type 1 Expression of Human cDNA from the Corresponding Mouse Promoter
  • the targeting vectors are constructed with standard molecular cloning procedures. These vectors are designed in such a way, that the cDNA of human MDR1 is fused to the translational start site of the corresponding mouse genes (Mdr1a and Mdr1b).
  • the Mdr1a targeting vector carries an FRT-flanked hygromycin resistance cassette, the Mdr1b targeting vector an F3-flanked neomycin resistance cassette. In both cases the transcripts are terminated by a polyA motif.
  • the targeting event removes the 3′part of exon2, in case of Mdr1b the 3′part of exon2 to exon4 are deleted. See FIGS. 4 and 5 .
  • Type 2 Expression of a Fusion of Mouse Gene and Human cDNA from the Corresponding Mouse Promoter
  • the targeting vector is constructed with standard molecular cloning procedures.
  • the vector is designed in such a way, that the “Leader sequence” of the mouse protein, which is encoded by exon1, will be retained.
  • the human cDNA without sequences from exon1 is introduced into exon2.
  • the original splice sites for mouse intron1 will be retained, so that this construct potentially encodes a fusion protein of amino acids from mouse exon1 and human exon2-32.
  • the transcript is terminated by a polyA motif.
  • the targeting vector carries an FRT-flanked neomycin resistance cassette (see FIG. 6 ).
  • the targeting vector is transfected by standard electroporation into C57BL/6N mouse ES cells. Clones are selected with G418 and positive clones are identified by Southerm blot analysis. Selected clones are expanded, injected into BALBc-blastocysts and transferred into foster mothers according to standard operation procedures. Litters from these fosters are visually inspected and chimerism is determined by hair colour. Highly chimeric animals are used for further breeding in a C57BL/6N genetic background. Selection markers are removed in vivo by crossing to an FLP-deleter strain.
  • Type 3 Expression of a Hybrid of Human cDNA and Genomic Sequences from the Corresponding Mouse Promoter
  • the targeting vector is constructed with standard molecular cloning procedures.
  • the vector is designed in such a way, that a hybrid of human PXR cDNA and genomic sequences is fused to the translational start site of the mouse PXR gene, whereby the mouse Start-ATG is retained.
  • the human PXR sequence contains the cDNA of exon1-4, genomic sequences of intron4, exon5 and intron5 and cDNA of exon6-9. This human PXR sequence is provided herein as SEQ ID NO:1.
  • the transcript is terminated by a polyA motif.
  • the targeting vector carries an FRT-flanked hygromycin resistance cassette and a splice acceptor polyA motif 3′ to the selection cassette.
  • the targeting vector is transfected by standard electroporation into C57BL/6N mouse ES cells. Clones are selected with hygromycin and positive clones are identified by Southerm blot analysis. Selected clones are expanded, injected into BALBc-blastocysts and transferred into foster mothers according to standard operation procedures. Litters from these fosters are visually inspected and chimerism is determined by hair colour. Highly chimeric animals are used for further breeding in a C57BL/6N genetic background. Selection markers are removed in vivo by crossing to an FLP-deleter strain.
  • mice for PXR have been generated using the above strategy and are phenotypically normal following visual inspection. They have been typed using PCR (see FIG. 15 ). The mice live to at least 3 months age. Examples include male “30643”: DOB Dec. 12, 2004. Remained alive at Apr. 19, 2005. Female “30792”: DOB Dec. 19, 2004. Remained alive at Apr. 19, 2005. These mice can be successfully bred:
  • RT-PCR was then performed to confirm the presence of a full-length human PXR transcript in the humanised mice (see FIG. 17 ).
  • This analysis demonstrated the presence of two transcripts of size 1.3 and 1.1 kilo-bases, indicating that the entire humanised PXR gene had been transcribed.
  • the size of the fragments obtained indicated that the correct, as well as alternative spliced variants were present.
  • mice were challenged with PXR-activating compounds including pregnenolone-16a carbonitrile (PCN), dexamethasone, TCPOBOP and rifampicin (Rif). While rifampicin is reported to be a more potent PXR inducer in humans, dexamethasone and PCN are reported to be more potent inducers in mice. Thus, these inducers enable the PXR phenotype of the non-human animals, tissues and cells of the invention to be discriminated.
  • PXR-activating compounds including pregnenolone-16a carbonitrile (PCN), dexamethasone, TCPOBOP and rifampicin (Rif). While rifampicin is reported to be a more potent PXR inducer in humans, dexamethasone and PCN are reported to be more potent inducers in mice. Thus, these inducers enable the PXR phenotype of the non-human animals, tissues and cells of the invention to be discriminated.
  • Dosing solutions were prepared on the day of administration by adding corn oil to the requisite quantity of test substance and stirring to obtain a solution or fine suspension.
  • concentration of PCN was 10 mg/ml and Rif 2.5 mg/ml of supplied chemical, without any correction for purity. Records of preparation were retained.
  • Control animals were administered vehicle (corn oil) daily by intraperitoneal injection.
  • the volume of vehicle and solutions of inducing agents administered was 10 ml/kg bodyweight. This route of administration was chosen for consistency with previously published work. Animals received 4 daily doses and were killed approximately 24 hours after the last dose.
  • mice were challenged with low doses of rifampicin or TCPOBOP. These compounds were chosen because rifampicin has been reported to be a more efficient inducer of human PXR than murine transcription factor, and TCPOBOP is reported to be a more efficient inducer of cytochrome P450 gene expression in the mouse than in human systems.
  • mice were treated with either corn oil daily for 4 days or mice administered a single injection of corn oil.
  • the treated mice were dosed with inducing agents as detailed in Table 3.1.
  • PXR activity was determined by measuring the metabolism of a number of cytochrome P450 substrates which are metabolised to different extents by different cytochrome P450 enzymes. The following assays were performed:
  • Cyp3a11 was quantified by SDS-PAGE followed by Western blotting and densitometric quantification ( FIG. 29 ). A clear difference was observed between huPXR and wild-type mice. Induction of the expression of the Cyp3a11 protein clearly began to increase at lower rifampicin doses in huPXR mice than in the wild-type mice.
  • huPXR mice The response of huPXR mice to administration of dexamethasone was evaluated in comparison to wild-type mice in an induction study. Increasing amounts of dexamethasone (0, 1, 3, 10 mg/kg mouse body weight) were administered to wild-type and huPXR mice ( FIG. 30 ).
  • Cyp3a11 was measured by SDS-PAGE followed by Western blotting ( FIG. 30 ). A clear difference was observed between huPXR and wild-type mice. Cyp3a11 expression was induced by increasing amounts of dexamethasone only in the wild-type mouse (i.e. not in the huPXR mouse).
  • Humanised PXR mice have a number of utilities. For example, such mice can be used to understand the role of human PXR in the control of gene expression in any tissue in the mouse. They can also be used to evaluate whether drugs in development or environmental chemicals have the capacity to modulate human PXR functions in a manner which may be beneficial or deleterious.
  • the model also allows studies into understanding the role of human PXR in mediating the potential toxic effects of drugs or chemicals which may result from perturbations in, for example, bile acid homeostasis and therefore their relevance to man.
  • the model can also be used to evaluate chemicals that may be either antagonistic or agonistic to this signalling pathway.
  • the inventors have performed numerous further experiments to confirm the functional validation of the huPXR and koPXR mice.
  • Cyp3a11 Upon administration of 60 mg rifampicin per kg body weight to wild-type, huPXR or koPXR mice, expression of Cyp3a11 was increased in both wild-type and huPXR, but not in koPXR mice. Experiments were conducted in triplicate. Cyp3a11 expression levels were measured by SDS-PAGE followed by Western blotting. Both pooled and individualized results of the Western blotting experiments are shown in FIG. 32 .
  • Cyp3a11 Upon administration of 60 mg dexamethasone (Dex) per kg body weight to wild-type, huPXR or koPXR mice, expression of Cyp3a11 was substantially increased in wild-type mice, somewhat less increased in huPXR mice, and only marginally increased in koPXR mice. Experiments were conducted in triplicate. Cyp3a11 expression levels were measured by SDS-PAGE followed by Western blotting. Both pooled and individualized results of the Western blotting experiments are shown in FIG. 34 .
  • ALT alanine aminotransferase
  • FIG. 36 the results of the BQ demethylation activity assay obtained at the same dosage of dexamethasone are shown for comparison (black bars: untreated control; white bars: 60 mg/kg dexamethasone).
  • Liver/body weight ratios of wild-type, huPXR and koPXR mice were measured following administration of either rifampicin or dexamethasone. In each case, the ratio was greatest for the koPXR strain ( FIG. 37 ).
  • FIG. 38 provides a summary of the effects of rifampicin and dexamethasone (each at 60 mg/kg) on Cyp3a11 and Cyp2b10 expression, in wild-type, huPXR and koPXR mice.
  • Type 4 Expression of a Human Genomic Sequence from the Corresponding Mouse Promoter
  • the targeting vector is constructed with standard molecular cloning procedures.
  • the vector is designed in such a way, that the genomic human CAR sequence is fused to the translational start site of the mouse CAR gene.
  • the human CAR sequence contains all genomic sequences of exons 1-9, except the 5′ and 3′UTRs, which are retained from the mouse genome. This human CAR sequence is provided herein as SEQ ID NO:2. All other parts of the coding sequences of the mouse CAR gene will be deleted.
  • the transcript is terminated by a polyA motif.
  • the targeting vector carries an FRT-flanked neomycin resistance cassette.
  • Att sites have been inserted into human intron2 and 3′ to the selection marker, which allow the generation of a CAR knock out by removal of the intermediate sequences with the site-specific Phi-C31 recombinase (see FIG. 8 ).
  • the targeting vector is transfected by standard electroporation into PXR humanized C57BL/6N mouse ES cells. Clones are selected with hygromycin and positive clones are identified by Southern blot analysis. Selected clones are expanded, injected into BALBc-blastocysts and transferred into foster mothers according to standard operating procedures. Litters from these fosters are visually inspected and chimerism is determined by hair colour. Highly chimeric animals are used for further breeding in a C57BL/6N genetic background. Selection markers are removed in vivo by crossing to an FLP-deleter strain.
  • the targeting vector is transfected by standard electroporation into C57BL/6N mouse ES cells. Clones are selected with hygromycin and positive clones are identified by Southern blot analysis. Selected clones are expanded, injected into BALBc-blastocysts and transferred into foster mothers according to standard operation procedures. Litters from these fosters are visually inspected and chimerism is determined by hair colour. Highly chimeric animals are used for further breeding in a C57BL/6N genetic background. Selection markers are removed in vivo by crossing to an FLP-deleter strain.
  • Liver/body weight ratios of wild type, koCAR and koPXR mice are shown in FIG. 40 , for untreated animals, and animals treated with dexamethasone or phenobarbital.
  • plasma levels of alanine aminotransferase (ALT), alkaline phosphatase (ALP) and aspartate aminotransferase (AST) were also measured (see FIG. 40 ).
  • No hepatotoxicity was detected in the wild-type, koPXR or koCAR mice at the doses of dexamethasone and phenobarbital tested. Both compounds were administered at 40 mg/kg.
  • Cyp3a11 and Cyp2b10 expression in the liver of wild-type, koCAR and koPXR mice was analysed by Western blotting for untreated animals and animals treated with dexamethasone (40 mg/kg) or phenobarbital (40 mg/kg). Pentoxyresurfin-O-deethylation (PROD) activity, which is reflective of Cyp2b10 expression and CAR activity, was analysed in the same animals. The results of these analyses are shown in FIG. 41 . In koCAR mice, phenobarbital-induced expression of both Cyp3a11 and Cyp2b10 was significantly reduced. However, expression of both Cyp3a11 and Cyp2b10 was still induced by dexamethasone treatment in koCAR mice, as was PROD activity.
  • Cyp2b10 expression in the gut of wild-type, koCAR and koPXR mice was also analysed by Western blotting for untreated animals and animals treated with dexamethasone (40 mg/kg) or PB (40 mg/kg). These results are compared with the results of the equivalent study in liver in FIG. 42 .
  • the induction of Cyp210 expression by dexamethasone observed in liver of koCAR mice was not observed in gut tissue.
  • Cyp2b10 expression in liver was also compared in koCAR and wild type mice after treatment with TCPOBOP (1 mg/kg). The results of densitometric quantification of Western blot bands obtained from liver samples are shown in FIG. 43 . In contrast to the wild type, no Cyp2b10 was induced at 1 mg/kg TCPOBOP in koCAR mice.
  • Liver/body weight ratios of wild type and huCAR mice are shown in FIG. 46 for untreated animals, and animals treated with 1, 10 or 50 mg/kg of the human CAR activator CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime; Maglich et al., J Biol. Chem. 2003 May 9; 278(19):17277-83). Plasma levels of alanine aminotransferase (ALT), alkaline phosphatase (ALP) and aspartate aminotransferase (AST) were also measured (see FIG. 46 ).
  • ALT alanine aminotransferase
  • ALP alkaline phosphatase
  • AST aspartate aminotransferase
  • Cyp3a11 and Cyp2b10 expression may each be specifically assessed by means of the 7-benzylquinoline (BQ) assay and the pentoxyresorufin-O-deethylation (PROD) assay, respectively.
  • BQ 7-benzylquinoline
  • PROD pentoxyresorufin-O-deethylation
  • Cyp2b10 was shown by Western blotting and the PROD activity assay to be induced by 1 mg/kg TCPOBOP in wild type mice, but not in huCAR mice ( FIG. 49 ; experiments conducted in triplicate). This is consistent with the observation that TCPOBOP induces cytochrome P450 metabolism more strongly in mice than in humans.
  • Dexamethasone which has been reported to induce cytochrome P450 metabolism more strongly in mice than in humans, induced Cyp2b10 expression in both wild-type and huCAR mice when administered at 10 mg/kg.
  • Western blots indicate that induction is less pronounced in huCAR than in wild-type mice ( FIG. 52 ), and the PROD activity assay confirmed that Cyp2b10 induction by dexamethasone was weaker in huCAR than in wild type mice. This result further confirms successful humanisation of the CAR-mediated response to cytochrome P450 inducers in huCAR mice.
  • Cyp2b10 induction by either CITCO or TCPOBOP in wild-type, huCAR, koCAR, huPXR (CITCO only) and koPXR mice is compared in FIG. 53 .
  • Cyp2b10 was not substantially induced by CITCOO in wild-type mice. Some induction was also observed in koPXR mice, which is consistent with the dependence of Cyp2b10 on CAR rather than PXR.
  • FIG. 83 An overview of various inducing agents on PXR and CAR target genes in wild-type, huPXR, koPXR, huCAR and koCAR mice is provided in FIG. 83 .
  • Non-genotoxic Carcinogenicity Study in huCAR Mice Demonstration of CAR-dependent Species-specific Differences in Wild-type and huCAR Mice
  • the fraction of BrdU positive cells in the liver was determined in wild-type and huCAR treated with CAR activators. Animals were treated either with TCPOBOP (a mouse-specific inducer) or CITCO (a human-specific inducer). Animals received a single dose of TCPOBOP (3 mg/kg) or 20 mg/kg CITCO 4 times daily. The fraction of BrdU positive cells in the liver of treated mice were determined one day after administration of the single or final dose, and compared to equivalent measurements obtained from untreated animals. As is shown in FIG.
  • the mouse-specific inducer TCPOBOP led to elevated counts of BrdU positive liver cells only in wild-type animals
  • human-specific inducer CITCO led to elevated counts of BrdU positive liver cells only in huCAR animals, not in the wild-type.
  • mice for PXR and CAR (“huPXR/huCAR”) were generated using mice which contained humanised PXR and crossing these into mice which contained humanised CAR to produce mice containing both humanised PXR and humanised CAR.
  • the mice are phenotypically normal following visual inspection. They have been typed using PCR (see FIG. 28 ) and are homozygously humanised for PXR and CAR. Examples include mice designated “42749” and “42752”.
  • Double-humanised huPXR/huCAR mice, as well as wild-type, huPXR and huCAR mice were treated with the inducers rifampicin and/or phenobarbital. Expression of Cyp2b10 and Cyp3a11 in these inducer-treated mice, as well as in corresponding untreated mice, was visualised and compared by SDS-PAGE followed by Western blotting ( FIG. 58 ). The basal levels of Cyp2b10 and Cyp3a11 in huPXR, huCAR and huPXR/huCAR mice are compared to the basal levels observed in wild-type mice in FIG. 58 .
  • mice were given a single intraperitoneal dose of Narcoren (sodium pentobarbitone; purchased via a Veterinary Consultant; distributed by Merial GmbH, Germany) at 25 mg/kg of body weight. The time taken for the mice to lose, and subsequently to regain, their righting reflex was measured. Results are given in Table 4.1 below:
  • mice which contained humanised PXR have also been crossed into mice which contained humanised CAR to produce mice containing both humanised PXR and humanised CAR.
  • Type 5 Expression of a Hybrid of Human cDNA and Genomic Sequences from the Corresponding Human Promoter by Insertion into the ROSA26 Locus
  • the targeting vectors are constructed with standard molecular cloning procedures.
  • the basic ROSA26 targeting vector is designed in a way, that the neomycin gene will be expressed from the endogenous ROSA26 promoter in correctly targeted ES clones.
  • the Neo transcript is terminated by a polyA motif.
  • the humanization cassette 3′ to the selection marker, contains the 13 kb human CYP3A4 promoter, exon1 and intron1 as in the normal genomic constitution and a human cDNA consisting of exons2-13.
  • the transcript is terminated by a polyA motif (see FIG. 9 ).
  • the humanization cassette 3′ to the selection marker, contains the 12 kb human CYP2C9 promoter, a human cDNA of exons1-4, intron4 and a cDNA of exons5-9.
  • the transcript is terminated by a polyA motif (see FIG. 10 ).
  • the targeting vector is transfected by standard electroporation into C57BL/6N mouse ES cells. Clones are selected with G418 and positive clones are identified by Southern blot analysis. Selected clones are expanded, injected into BALBc-blastocysts and transferred into foster mothers according to standard operation procedures. Litters from these fosters are visually inspected and chimerism is determined by hair colour. Highly chimeric animals are used for further breeding in a C57BL/6N genetic background.
  • the targeting vectors are constructed with standard molecular cloning procedures.
  • the general principle is that two kinds of targeting vectors are constructed and used for two consecutive rounds of transfection by standard electroporation into C57BL/6N mouse ES cells.
  • the first vector contains a functional TK cassette and a 5′ deleted Neo gene interrupted from its tranlational Start-ATG and promoter by a wt-loxP site.
  • the second vector carries functional TK and Hygromycin cassettes, a wt-loxP and a lox511 site.
  • the final targeting vectors for each of the cluster exchanges are designed in such a way, that in correctly targeted ES clones the genomic sequences intermediate to the wt-loxP sites can be removed by Cre-mediated deletion.
  • BACs Bacterial Artificial Chromosomes
  • the targeting vectors are constructed with standard molecular cloning procedures. For all reporters human BACs are modified in such a way, that a reporter gene is fused to the translational start site of the corresponding human gene. Modified BACs carry an FRT-flanked Keo cassette, permitting the selection of bacterial colonies with kanamycin and mouse ES cell clones with G418. In case of CYP3A4, CYP2C9 and CYP2C19 the transcript of the reporter gene is not terminated by a polyA motif, but the constructs are designed such, that the endogenous polyA motif is potentially used. These constructs are therefore dependent on a correct splicing of the exons 3′ to the reporter (see FIG. 12 ).
  • the transcript of the reporter gene is terminated by a polyA motif linked to the reporter gene with a synthetic intron (see FIG. 13 ).
  • the transcript of the reporter gene is terminated by a polyA motif without an additional intron (see FIG. 14 ).
  • the modified BAC are linearized with NotI and transfected into C57BL/6N mouse ES cells either by standard electroporation or lipofection with lipofectamin2000.
  • the linearized modified BAC are transfected into an appropriate genetic background.
  • the BAC is transfected into PXR or CAR humanized C57BL/6N mouse ES cells.
  • Clones are selected with G418 and positive clones with randomly integrated DNA are identified by PCR analysis. Selected clones are expanded, injected into BALBc-blastocysts and transferred into foster mothers according to standard operation procedures. Litters from these fosters are visually inspected and chimerism is determined by hair colour. Highly chimeric animals are used for further breeding in a C57BL/6N genetic background. Selection markers are removed in vivo by crossing to an FLP-deleter strain.
  • the complex-genotype strain rCyp2B6/huCAR was generated according to the methods described herein and the targeting strategy provided herein (see Example 5 below for further details of preferred rCyp2b6 strains) and using standard methods that are well known to persons skilled in the art.
  • Expression of the lacZ reporter gene was placed under the control of the Cyp2b6 promoter in a huCAR background.
  • FIG. 59 shows tissue samples from wild-type and rCyp2b6/huCAR reporter mice (liver microsomes). After administration of 40 mg phenobarbital per kg body weight, the lacZ reporter gene allows straightforward localisation of Cyp2b6 promoter activity.
  • the complex-genotype strain rCyp2d6/huPXR was generated according to the methods described above and the targeting strategy provided herein (see Example 5, below for further details of preferred rCyp2d6 strains) and using standard methods that are well known to persons skilled in the art. Expression of the ZsYellow reporter gene was thus placed under the control of the Cyp2d6 promoter in a huPXR background.
  • FIG. 60 shows tissue samples from wild-type and rCyp2d6/huPXR reporter mice (liver microsomes).
  • the ZsYellow reporter gene allowed the clear localisation of Cyp2d6 promoter activity.
  • the vectors are designed such that a hybrid of human PXR cDNA and genomic sequences is fused to the translational start site of the mouse PXR gene, whereby the mouse start site (ATG) in exon2 is retained.
  • the human PXR sequence contains a cDNA of exon2-4, genomic sequences of intron4, exon5, intron5, exon6, intron6, exon7 and intron7 and a cDNA of exon8-9 (see FIG. 61 ).
  • This human PXR sequence is provided herein as SEQ ID NO:3 (in this sequence, the human “CTG” has been deleted and the initial “ATG” of SEQ ID NO:3 corresponds to the start site for translation in the mouse).
  • the transcript is terminated by a polyA motif.
  • the targeting vector carries an FRT-flanked hygromycin resistance cassette.
  • FIG. 62 A representation of the complete targeting vector comprising the above features is provided in FIG. 62 .
  • the targeting vector is transfected by standard electroporation into C57BL/6N mouse ES cells. Clones are selected with hygromycin and positive clones are identified by Southern blot analysis. Selected clones are expanded, injected into BALBc-blastocysts and transferred into foster mothers according to standard operation procedures. Litters from these fosters are visually inspected and chimerism is determined by hair colour. Highly chimeric animals are used for further breeding in a C57BL/6N genetic background. Selection markers are removed in vivo by crossing to an FLP-deleter strain.
  • Such PXR humanisation strategies wherein the targeting construct contains PXR intron6 and intron7 provide mouse lines that are humanised with respect to PXR, but might not fully reflect the normal splicing pattern in humans (e.g. if a cryptic splice site is created by fusing exon7 and 8). Additional human PXR intron and exon sequences can be included in the targeting vector to improve the splicing pattern, if desired.
  • the targeting vector may retain all of the human PXR genomic sequences downstream of exon 2 (i.e., intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7, intron 7, exon 8 and intron 8 (see FIG. 63 ).
  • a human PXR sequence including these additional genomic sequences is provided herein as SEQ ID NO:4 (in this sequence, the human “CTG” has been deleted and the initial “ATG” of SEQ ID NO:4 corresponds to the start site for translation in the mouse).
  • targeting construct shown in FIG. 2 is preferred for generating PXR knock-out mice, because that targeting construct contains an additional splice acceptor polyA motif to prevent expression of undeleted mouse PXR exons.
  • a preferred human CAR sequence is provided herein as SEQ ID NO:2. This sequence contains a 53 bp Phi-C31 recognition site (attB53) within intron2.
  • a preferred targeting strategy is shown in FIG. 65 .
  • a preferred targeting vector is shown in FIG. 66 .
  • a DNA sequence encoding human PPAR ⁇ is inserted into the mouse PPAR ⁇ locus, as shown in FIG. 67 , enabling expression of human PPAR ⁇ under the control of the mouse PPAR ⁇ promoter.
  • the DNA sequence encoding human PPAR ⁇ comprises at least part of intron 5 and intron 6 of the human PPAR ⁇ gene ( FIG. 67 ).
  • the targeting vector(s) include sequence elements that enable Cre-mediated PPAR ⁇ knock-out to produce koPPAR ⁇ ( FIG. 67 ).
  • a DNA sequence encoding human AhR is inserted into the mouse AhR locus (knock-in) as shown in FIG. 68 , enabling expression of human AhR under the control of the mouse AhR promoter.
  • the DNA sequence encoding human AhR comprises exons 3-11 of the human AhR gene ( FIG. 68 ).
  • the targeting vector(s) include sequence elements that enable Cre-mediated AhR knock-out to produce koAhR ( FIG. 68 ).
  • a DNA sequence encoding human CYP3A4 is inserted into the mouse Rosa26 locus (knock-in), as shown in FIG. 69 , enabling expression of human CYP3A4 under the control of a human CYP3A4 promoter.
  • the DNA sequence encoding human CYP3A4 preferably comprises intron 1 of the human CYP3A4 gene.
  • the ZsGreen reporter gene is inserted into the mouse Cyp3a11 locus by homologous recombination, as shown in FIG. 70 , eliminating expression of mouse Cyp3a11, and enabling ZsGreen under the control of the mouse Cyp3a11 promoter.
  • a DNA sequence encoding the human CYP3A cluster is inserted into the loxP-flanked mouse CYP3A cluster, as shown in FIG. 71 , enabling expression of the human CYP3A cluster under the control of human CYP3A promoters.
  • the targeting vector includes loxP sequence elements that enable Cre-mediated deletion of the mouse CYP3A cluster, to produce koCYP3A (see FIG. 71C ). Cre-mediated deletion of the mouse CYP3A cluster is followed by Cre-mediated insertion of the human CYP3A cluster, to produce huCYP3A ( FIG. 71C ). After the insertion of the human CYP3A cluster into the mouse CYP3A cluster, selection cassettes are deleted, using FRT sites that are also present in the targeting vector ( FIG. 71C ).
  • a DNA sequence encoding human CYP3A4 is inserted into the mouse Cyp3a cluster at the Cyp3a25 locus, enabling expression of human CYP3A4 under the control of the 13 kb human CYP3A4 promoter. Mice in which the mouse Cyp3a cluster is deleted may also be generated.
  • a DNA sequence encoding human CYP2C9 is inserted into the mouse Rosa26 locus, as shown in FIG. 72 , enabling expression of human CYP2C9 under the control of the 12 kb human CYP2C9 promoter.
  • the DNA sequence encoding human CYP2C9 comprises a 1,2 kb sequence of human CYP2C9 intron 4 ( FIG. 72 ).
  • a DNA sequence encoding the human CYP2C cluster is inserted into the mouse CYP2C cluster, as shown in FIG. 73 , enabling expression of the human CYP2C cluster under the control of human CYP2C promoters.
  • the targeting vector includes loxP sequence elements that enable Cre-mediated deletion of the mouse CYP2C cluster, to produce koCYP2C ( FIG. 73C ). Cre-mediated deletion of the mouse CYP2C cluster is followed by Cre-mediated insertion of the human CYP2C cluster, to produce huCYP2C ( FIG. 73C ). After the insertion of the human CYP2C cluster into the mouse CYP2C cluster, selection cassettes are deleted, using FRT sites that are also present in the targeting vector ( FIG. 73C ).
  • a DNA sequence encoding human CYP2C9 is inserted into the mouse Cyp2c cluster, enabling expression of human CYP2C9 under the control of the 12 kb human CYP2C9 promoter. Mice in which the mouse Cyp2c cluster is deleted may also be generated.
  • a DNA sequence encoding human CYP2D6 is inserted into the mouse Cyp2d cluster, enabling expression of human CYP2D6 under the control of the 9 kb human CYP2D6 promoter. Mice in which the mouse Cyp2d cluster is deleted may also be generated.
  • a DNA sequence encoding human CYP3A4 is inserted into the mouse Cyp3a cluster at the Cyp3a11 locus, enabling expression of human CYP3A4 under the control of the mouse Cyp3a11 promoter. Mice in which the mouse Cyp3a cluster is deleted may also be generated.
  • DNA sequences encoding human CYP1A1 and human CYP1A2 are inserted into the mouse Cyp1a cluster, enabling expression of human CYP1A1 and human CYP1A2 under the control of the human CYP1A1 and CYP1A2 promoters. Mice in which the mouse Cyp1a cluster is deleted may also be generated.
  • a DNA sequence encoding the human Ugt1 cluster is inserted into the mouse Ugt1 cluster, as shown in FIG. 74 , enabling expression of the human Ugt1 cluster under the control of human Ugt1 promoters.
  • the targeting vector includes loxP sequence elements that enable Cre-mediated deletion of the mouse Ugt1 cluster, to produce koUGT ( FIG. 74C ). Cre-mediated deletion of the mouse Ugt1 cluster is followed by Cre-mediated insertion of the human Ugt1 cluster, to produce huUGT ( FIG. 74C ). After the insertion of the human Ugt1 cluster into the mouse Ugt1 cluster, selection cassettes are deleted, using FRT sites that are also present in the targeting vector ( FIG. 74C ).
  • a DNA sequence encoding human MDR1 is inserted into the mouse Mdr1a locus, as shown in FIG. 75 , enabling expression of human MDR1 under the control of the mouse Mdr1a promoter.
  • the DNA sequence encoding human MDR1 is the human MDR1 cDNA sequence, starting with the initial ATG.
  • a DNA sequence encoding human MDR1 is inserted into the mouse Mdr1b locus, as shown in FIG. 76 , enabling expression of human MDR1 under the control of the mouse Mdr1b promoter.
  • the DNA sequence encoding human MDR1 is the human MDR1 cDNA sequence, starting with the initial ATG.
  • the targeting is achieved in the same way as for the Mdr1a and Mdr1b single humanisation, wherein Mdr1b is targeted as shown in FIG. 76 in ES cells that have previously been manipulated at the Mdr1a locus according to the strategy provided in FIG. 75 .
  • the cDNA sequence encoding human MPR2 is inserted into the mouse Mrp2 locus, as shown in FIG. 77 , enabling expression of human MRP2 under the control of the mouse Mrp2 promoter.
  • the mouse leader encoded by exon 1 is retained,
  • the human cDNA will be introduced on exon2, and splice site retained,
  • the human transcript is terminated by a polyA motif, and
  • the complete intron 2 sequence is retained.
  • the LacZ reporter gene and the transcriptionally linked human CYP2B6 promoter are inserted into exon 1 of the mouse Cyp2b6 locus in BL6 ES cells, as shown in FIG. 78 .
  • the selection marker keo is deleted using the FRP sites and FLP recombinase, as indicated in FIG. 79 . This strategy allows expression of the LacZ reporter gene in mice under the control of the human CYP2B6 promoter.
  • the ZsYellow reporter gene and the transcriptionally linked human CYP2D6 promoter are inserted into exon 1 of the mouse Cyp2d6 locus in BL6 ES cells, as shown in FIG. 79 .
  • the selection marker keo is deleted using the FRP sites and FLP recombinase, as indicated in FIG. 79 . This strategy allows expression of the ZsYellow reporter gene in mice under the control of the human CYP2D6 promoter.
  • the hCG-ZsGreen reporter gene and the transcriptionally linked human CYP3A4 promoter are inserted into exon 1 of the mouse Cyp3a4 locus in BL6 ES cells, as shown in FIG. 80 .
  • the selection marker keo is deleted using the FRP sites and FLP recombinase, as indicated in FIG. 80 . This strategy allows expression of the hCG-ZsGreen reporter gene in mice under the control of the human CYP3A4 promoter.
  • the Firefly luciferase reporter gene is inserted into exon 1 of the mouse Cyp3a11 locus, as shown in FIG. 81 .
  • This strategy allows expression of the hCG-ZsGreen reporter gene in mice under the control of the mouse Cyp3a11 promoter.
  • the procedure is alternatively carried out using the ZsGreen reporter gene ( FIG. 70 ).
  • MDR1 multidrug resistance

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US11/757,972 2004-12-13 2007-06-04 Transgenic animals for assessing drug metabolism and toxicity Expired - Fee Related US7759541B2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US11/757,972 US7759541B2 (en) 2004-12-13 2007-06-04 Transgenic animals for assessing drug metabolism and toxicity
US12/602,723 US8624079B2 (en) 2007-06-04 2008-06-04 Knockin mouse with a disruption in a PXR gene expressing human PXR
JP2010510871A JP2010528644A (ja) 2007-06-04 2008-06-04 薬物の代謝及び毒性を評価するためのトランスジェニック動物
IN7390DEN2009 IN2009DN07390A (enExample) 2007-06-04 2008-06-04
PCT/GB2008/001897 WO2008149080A1 (en) 2007-06-04 2008-06-04 Transgenic animals for assessing drug metabolism and toxicity
EP08762250A EP2173160A1 (en) 2007-06-04 2008-06-04 Transgenic animals for assessing drug metabolism and toxicity
CA002688438A CA2688438A1 (en) 2007-06-04 2008-06-04 Transgenic animals for assessing drug metabolism and toxicity
AU2008259618A AU2008259618A1 (en) 2007-06-04 2008-06-04 Transgenic animals for assessing drug metabolism and toxicity
IL202127A IL202127A0 (en) 2007-06-04 2009-11-15 Transgenic animals for assessing drug metabolism and toxicity
US12/787,816 US8212105B2 (en) 2004-12-13 2010-05-26 Transgenic mice for assessing drug metabolism and toxicity

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0427172A GB0427172D0 (en) 2004-12-13 2004-12-13 Transgenic animals for assessing drug metabolism and toxicity
GB0427172.2 2004-12-13
GB0516187A GB0516187D0 (en) 2005-08-05 2005-08-05 Transgenic animals for assessing drug metabolism and toxicity
GB0516187.2 2005-08-05
US70707705P 2005-08-10 2005-08-10
PCT/GB2005/004772 WO2006064197A2 (en) 2004-12-13 2005-12-13 Transgenic animals for assessing drug metabolism and toxicity
US11/757,972 US7759541B2 (en) 2004-12-13 2007-06-04 Transgenic animals for assessing drug metabolism and toxicity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004772 Continuation-In-Part WO2006064197A2 (en) 2004-12-13 2005-12-13 Transgenic animals for assessing drug metabolism and toxicity

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/602,723 Continuation US8624079B2 (en) 2007-06-04 2008-06-04 Knockin mouse with a disruption in a PXR gene expressing human PXR
US12/602,723 Continuation-In-Part US8624079B2 (en) 2007-06-04 2008-06-04 Knockin mouse with a disruption in a PXR gene expressing human PXR
US12/787,816 Division US8212105B2 (en) 2004-12-13 2010-05-26 Transgenic mice for assessing drug metabolism and toxicity

Publications (2)

Publication Number Publication Date
US20080148416A1 US20080148416A1 (en) 2008-06-19
US7759541B2 true US7759541B2 (en) 2010-07-20

Family

ID=39698732

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/757,972 Expired - Fee Related US7759541B2 (en) 2004-12-13 2007-06-04 Transgenic animals for assessing drug metabolism and toxicity
US12/602,723 Expired - Fee Related US8624079B2 (en) 2007-06-04 2008-06-04 Knockin mouse with a disruption in a PXR gene expressing human PXR
US12/787,816 Expired - Lifetime US8212105B2 (en) 2004-12-13 2010-05-26 Transgenic mice for assessing drug metabolism and toxicity

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/602,723 Expired - Fee Related US8624079B2 (en) 2007-06-04 2008-06-04 Knockin mouse with a disruption in a PXR gene expressing human PXR
US12/787,816 Expired - Lifetime US8212105B2 (en) 2004-12-13 2010-05-26 Transgenic mice for assessing drug metabolism and toxicity

Country Status (8)

Country Link
US (3) US7759541B2 (enExample)
EP (1) EP2173160A1 (enExample)
JP (1) JP2010528644A (enExample)
AU (1) AU2008259618A1 (enExample)
CA (1) CA2688438A1 (enExample)
IL (1) IL202127A0 (enExample)
IN (1) IN2009DN07390A (enExample)
WO (1) WO2008149080A1 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130117873A1 (en) * 2011-10-28 2013-05-09 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
US20140134662A1 (en) * 2012-11-05 2014-05-15 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
US20150143561A1 (en) * 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
US9155290B2 (en) * 2013-10-15 2015-10-13 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
US9301509B2 (en) 2009-10-06 2016-04-05 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US9655352B2 (en) 2011-02-15 2017-05-23 Regeneron Pharmaceuticals, Inc. Humanized M-CSF mice
US9730435B2 (en) * 2013-11-19 2017-08-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
US9820476B2 (en) 2012-09-07 2017-11-21 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US10123518B2 (en) 2015-04-13 2018-11-13 Regeneron Pharmaceuticals, Inc Genetically modified non-human animals and methods of use thereof
US10463028B2 (en) 2014-05-19 2019-11-05 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals expressing human EPO
US11716974B2 (en) 2016-06-27 2023-08-08 Baylor College Of Medicine Human liver chimeric mouse with deficient P450 oxidoreductase

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
EP2218786B1 (en) * 2007-11-14 2013-09-18 National University Corporation Tottori University Mammalian artificial chromosome vector comprising human cytochrome p450 gene (cluster), and non-human mammalian animal retaining the same
CN102286398B (zh) * 2010-06-21 2014-06-04 中国科学院上海生命科学研究院 一种生产高活性和高纯度利福霉素sv的方法
US20120023599A1 (en) * 2010-07-23 2012-01-26 Sigma-Aldrich Co. Genome editing of cytochrome p450 in animals
FR2979453B1 (fr) * 2011-08-26 2016-01-08 Olea Medical Systeme et procede pour estimer une quantite d'interet d'un systeme dynamique artere/tissu/veine
US20140273031A1 (en) * 2013-03-15 2014-09-18 The Cleveland Clinic Foundation In-vitro method for monoclonal antibody production
US9665718B2 (en) 2014-03-14 2017-05-30 International Business Machines Corporation Correlating a task with commands to perform a change ticket in an IT system
CN109182292B (zh) * 2018-09-25 2022-02-08 安徽农业大学 一种草莓谷胱甘肽转移酶FaGST基因及其表达蛋白和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083897A1 (en) 2001-04-18 2002-10-24 Gene Stream Pty Ltd Transgenic non-human animals for pharmacological and toxicological studies
WO2004007708A1 (en) 2002-07-12 2004-01-22 Imperial Cancer Research Technology Limited Modulation of cytochrome p450 reductase activity
US20040128703A1 (en) * 2002-09-09 2004-07-01 Hiroaki Shizuya Methods and compositions for the generation of humanized mice

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206906A4 (en) 1999-08-13 2004-12-29 Kirin Brewery MOUSE CONTAINING A HUMAN P450 CYTOCHROME
EP1088900A1 (en) 1999-09-10 2001-04-04 Epidauros Biotechnologie AG Polymorphisms in the human CYP3A4, CYP3A7 and hPXR genes and their use in diagnostic and therapeutic applications
CA2426959C (en) 2000-11-01 2011-10-04 The University Of Sydney Transgenic animals for analysing cyp3a4 cytochrome p450 gene regulation
JP2003304896A (ja) 2002-04-15 2003-10-28 Yasushi Yamazoe ヒトｃｙｐ３ａ誘導能の測定法
US7759541B2 (en) * 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
AU2005315438B2 (en) 2004-12-13 2012-02-23 Iti Scotland Limited Transgenic animals for assessing drug metabolism and toxicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083897A1 (en) 2001-04-18 2002-10-24 Gene Stream Pty Ltd Transgenic non-human animals for pharmacological and toxicological studies
WO2004007708A1 (en) 2002-07-12 2004-01-22 Imperial Cancer Research Technology Limited Modulation of cytochrome p450 reductase activity
US20040128703A1 (en) * 2002-09-09 2004-07-01 Hiroaki Shizuya Methods and compositions for the generation of humanized mice

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
Auerbach et al., Nucleic Acids Res., 2003, 31(12), 3194-3207.
Call, LM et al., "A cre-lox recombination system for the targeted integration of cirucular yeast artificial chromosomes into embryonic stem cells," Hum. Mol. Genet., 2000, 9(12), 1745-1751.
Chen, CJ et al., "Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins," J. Biol. Chem., 1990, 265(1), 506-514.
Erratum: Li, ZW et al., PNAS USA, 1996, 93(21), 12052.
Goodwin, B., et al., "Transcriptional Regulation of the Human CYP3A4 Gene by the Constitutive Androstane Receptor", Molecular Pharmacology, 2002, vol. 62, No. 2, 359-365.
Henderson, CJ et al., J. Biol. Chem., 2003, 278, 13480-13486.
Huang et al., Molecular Endocrinology, 2004, 18(10), 2402-2408.
Lehmann, J.M., et al., "The Human Orphan Nuclear Receptor PXR Is activated by Compounds That Regulate CYP34A Gene Expression and Cause Drug Interactions", J. Clinical Investigation, 1998, vol. 102, No. 5, 1016-1023.
Li, ZW et al., "Generation of mice with 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells," PNAS USA, 1996, 93(12), 6158-6162.
Ma (Drug Metab. Dispos. 2007, Vo. 35, No. 2, p. 194-200). *
Ma et al., Drug Metab. Dispos., 2007, 35(2), 194-200.
Ma et al., Drug Metab. Dispos., 2007, 35(2), 194-200.
Maglich et al., J. Biol. Chem., 2003, 278(19), 17277-17283.
Raguz, S. et al., "Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion," Clin Cancer Res., 2004, 10(8), 2776-2783.
Robertson, G.R. et al., "Transgenic Mouse Models of Human CYP3A4 Gene Regulation," Molecular Pharamacology, Baltimore, MD, 2003, 64(1), 42-50.
Robertson, Mol. Pharmacol., 2003, vol. 64, p. 42-50. *
Su, H. et al., "Nested chromosomal deletions induced with retroviral vectors in mice," Nat. Genet., 2000, 24(1), 92-95.
Ueda, K. et al., "Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene," J. Biol. Chem., 1987, 262(36), 17432-17436.
Xie (Drug discovery today, 2002, vol. 7, No. 9, p. 509-515). *
Xie et al., "Humanized xenobiotic response in mice expressing nuclear receptor SXR," Nature, 2000, 406(6794), 435-439.
Xie et al., Drug Discov Today, 2002, 7(9), DDT7, 509-515.
Xie, Nature, Jul. 27, 2000, vol. 406, p. 435-439. *
Zhang (Biochem. Pharmacol., 2003, vol. 65, p. 1889-1896). *
Zhang, J. et al., "Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR," Science, 2002, 298, 422-424.
Zhang, W. et al., "In vivo activation of the human CYP3A4 promoter in mouse liver and regulation by prename X receptors," Biochemical Pharmacology, 2003, 65(11), 1889-1896.

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11051499B2 (en) 2009-10-06 2021-07-06 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US12402611B2 (en) 2009-10-06 2025-09-02 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US10278374B2 (en) 2009-10-06 2019-05-07 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US9554563B2 (en) 2009-10-06 2017-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US9301509B2 (en) 2009-10-06 2016-04-05 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US9655352B2 (en) 2011-02-15 2017-05-23 Regeneron Pharmaceuticals, Inc. Humanized M-CSF mice
US12127536B2 (en) 2011-02-15 2024-10-29 Regeneron Pharmaceuticals, Inc. Humanized M-CSF mice
US10785966B2 (en) 2011-02-15 2020-09-29 Regeneron Pharmaceuticals, Inc. Humanized M-CSF mice
KR102234632B1 (ko) 2011-10-28 2021-04-02 리제너론 파아마슈티컬스, 인크. 사람화된 ｉｌ-6 및 ｉｌ-6 수용체
US12239111B2 (en) 2011-10-28 2025-03-04 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
US9125386B2 (en) * 2011-10-28 2015-09-08 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
US20150272092A1 (en) * 2011-10-28 2015-10-01 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
US10004211B2 (en) 2011-10-28 2018-06-26 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
US11102962B2 (en) 2011-10-28 2021-08-31 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
KR20200024949A (ko) * 2011-10-28 2020-03-09 리제너론 파아마슈티컬스, 인크. 사람화된 ｉｌ-6 및 ｉｌ-6 수용체
US9078418B2 (en) 2011-10-28 2015-07-14 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
US9392777B2 (en) * 2011-10-28 2016-07-19 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
US20150013022A1 (en) * 2011-10-28 2015-01-08 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
US9622460B2 (en) 2011-10-28 2017-04-18 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
KR102084927B1 (ko) 2011-10-28 2020-03-06 리제너론 파아마슈티컬스, 인크. 사람화된 ｉｌ-6 및 ｉｌ-6 수용체
US8878001B2 (en) * 2011-10-28 2014-11-04 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
US10433528B2 (en) 2011-10-28 2019-10-08 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
US20130117873A1 (en) * 2011-10-28 2013-05-09 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
KR20140091024A (ko) * 2011-10-28 2014-07-18 리제너론 파아마슈티컬스, 인크. 사람화된 ｉｌ-6 및 ｉｌ-6 수용체
US10314298B2 (en) 2012-06-18 2019-06-11 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
US9232776B2 (en) 2012-06-18 2016-01-12 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
US9974291B2 (en) 2012-06-18 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
US9737059B2 (en) 2012-06-18 2017-08-22 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
US11026408B2 (en) 2012-09-07 2021-06-08 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US9820476B2 (en) 2012-09-07 2017-11-21 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US10433527B2 (en) 2012-09-07 2019-10-08 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US12127537B2 (en) 2012-09-07 2024-10-29 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US11778995B2 (en) 2012-11-05 2023-10-10 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
KR20220075242A (ko) * 2012-11-05 2022-06-07 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR102768101B1 (ko) 2012-11-05 2025-02-18 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
US9901082B2 (en) * 2012-11-05 2018-02-27 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
KR20240042142A (ko) * 2012-11-05 2024-04-01 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
US20140134662A1 (en) * 2012-11-05 2014-05-15 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
KR102649893B1 (ko) 2012-11-05 2024-03-25 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR102275412B1 (ko) 2012-11-05 2021-07-12 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
US9986724B2 (en) 2012-11-05 2018-06-05 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
KR102402806B1 (ko) 2012-11-05 2022-05-30 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
US10785968B2 (en) * 2012-11-05 2020-09-29 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
KR20220148307A (ko) * 2012-11-05 2022-11-04 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR20210087567A (ko) * 2012-11-05 2021-07-12 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR102458016B1 (ko) 2012-11-05 2022-10-25 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR20150081285A (ko) * 2012-11-05 2015-07-13 리제너론 파마슈티칼스 인코포레이티드 유전자 변형된 비-인간 동물 및 그것의 사용 방법
US10561125B2 (en) 2013-10-15 2020-02-18 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
US11503813B2 (en) 2013-10-15 2022-11-22 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
US9155290B2 (en) * 2013-10-15 2015-10-13 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
US20150366175A1 (en) * 2013-10-15 2015-12-24 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
US12369570B2 (en) 2013-10-15 2025-07-29 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
US9730435B2 (en) * 2013-11-19 2017-08-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
US10219494B2 (en) * 2013-11-19 2019-03-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized B-cell activating factor gene
US11000020B2 (en) * 2013-11-19 2021-05-11 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized B-cell activating factor gene
RU2670016C1 (ru) * 2013-11-19 2018-10-17 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген фактора активации в-клеток
RU2671101C1 (ru) * 2013-11-19 2018-10-29 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
US9629347B2 (en) * 2013-11-19 2017-04-25 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized B-cell activating factor gene
US20150143558A1 (en) * 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
US12058987B2 (en) 2013-11-19 2024-08-13 Regeneron Pharmaceuticals, Inc. Mouse having a humanized B-cell activating factor gene
US20150143561A1 (en) * 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
US20190124897A1 (en) * 2013-11-19 2019-05-02 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
US11766032B2 (en) 2014-05-19 2023-09-26 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals expressing human EPO
US10463028B2 (en) 2014-05-19 2019-11-05 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals expressing human EPO
US10561126B2 (en) 2015-04-13 2020-02-18 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US10123518B2 (en) 2015-04-13 2018-11-13 Regeneron Pharmaceuticals, Inc Genetically modified non-human animals and methods of use thereof
US11576356B2 (en) 2015-04-13 2023-02-14 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US11716974B2 (en) 2016-06-27 2023-08-08 Baylor College Of Medicine Human liver chimeric mouse with deficient P450 oxidoreductase

Also Published As

Publication number Publication date
US20080148416A1 (en) 2008-06-19
US8212105B2 (en) 2012-07-03
EP2173160A1 (en) 2010-04-14
US20100257620A1 (en) 2010-10-07
IL202127A0 (en) 2010-06-16
JP2010528644A (ja) 2010-08-26
IN2009DN07390A (enExample) 2015-07-24
US20100235928A1 (en) 2010-09-16
AU2008259618A1 (en) 2008-12-11
CA2688438A1 (en) 2008-12-11
US8624079B2 (en) 2014-01-07
WO2008149080A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
US7759541B2 (en) Transgenic animals for assessing drug metabolism and toxicity
Bunger et al. Abnormal liver development and resistance to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-binding domain of the aryl hydrocarbon receptor
Scheer et al. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response
US7781643B2 (en) Transgenic non-human animals for pharmacological and toxicological studies
Wu et al. Conditional knockout of the mouse NADPH‐cytochrome p450 reductase gene
EP2209898B1 (en) Two step cluster deletion and humanisation
EP1827087B1 (en) Transgenic animals for assessing drug metabolism and toxicity
US8809619B2 (en) Knockout mice for a P450 gene cluster
Adams et al. Murine SEC24D can substitute functionally for SEC24C during embryonic development
Wang et al. SSTR5 ablation in islet results in alterations in glucose homeostasis in mice
HK1102391B (en) Transgenic animals for assessing drug metabolism and toxicity
US7186879B2 (en) Screening systems and methods for identifying modulators of xenobiotic metabolism
US20200085021A1 (en) Model system for mitochondrial dysfunction and methods of using the same
US20110119780A1 (en) Screening for non-genotoxic carcinogens
Class et al. Patent application title: SCREENING FOR NON-GENOTOXIC CARCINOGENS Inventors: Charles Roland Wolf (Dundee, GB) Clifford Roy Elcombe (Dundee, GB) Assignees: ITI SCOTLAND LIMITED
Bunger Mechanistic insight into the function of the PAS proteins AHR, ARNT and MOP3 using mouse models

Legal Events

Date Code Title Description
AS Assignment

Owner name: ITI LIFE SCIENCES, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FAUST, NICOLE;WOLF, CHARLES ROLAND;SCHEER, NICO;REEL/FRAME:019999/0560;SIGNING DATES FROM 20070910 TO 20071009

Owner name: ITI LIFE SCIENCES, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FAUST, NICOLE;WOLF, CHARLES ROLAND;SCHEER, NICO;SIGNING DATES FROM 20070910 TO 20071009;REEL/FRAME:019999/0560

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: ITI SCOTLAND LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WOLF, CHARLES ROLAND;SCHEER, NICO;FAUST, NICOLE;SIGNING DATES FROM 20130703 TO 20130704;REEL/FRAME:030747/0910

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552)

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20220720

AS Assignment

Owner name: TACONIC BIOSCIENCES, INC., NEW YORK

Free format text: ASSIGNATION AND LISCENSE TERMINATION;ASSIGNOR:ITI SCOTLAND LIMITED;REEL/FRAME:061740/0602

Effective date: 20180101

AS Assignment

Owner name: MIDCAP FINANCIAL TRUST, MARYLAND

Free format text: SECURITY INTEREST;ASSIGNOR:TACONIC BIOSCIENCES, INC.;REEL/FRAME:061608/0403

Effective date: 20221101